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1. INTRODUCTION {#med21552-sec-0010}
===============

Noninvasive imaging of neurotransmitter receptors with positron emission tomography (PET) provides insights into the number of receptors expressed in the brain and the functioning of brain networks. Analysis of the imaging data yields information about the role of particular neurotransmitters in the functioning of the brain in health as well as in neuropsychiatric disorders, including syndromes characterized by cognitive dysfunction.

Neurotransmitters bind to receptors that are either ligand‐gated ion channels (LGICs) or G‐protein‐coupled receptors (GPCRs). For some neurotransmitters, all receptors belong to a single receptor superfamily, for example, all known dopamine receptors are GPCRs. Other neurotransmitters bind to receptors from both superfamilies, for example, there are LGIC‐ and GPCR‐type receptors of the neurotransmitters acetylcholine and glutamate.

The signaling mechanism of LGICs is comparatively simple and quick---neurotransmitter binding opens the ionic channel that the receptor itself forms. A quick (millisecond time scale) and usually short‐lasting postsynaptic response is thus obtained. GPCRs, on the other hand, affect their downstream signaling pathways through the mediation of trimeric proteins called G‐proteins (Figure [1](#med21552-fig-0001){ref-type="fig"}). The GPCR signaling mechanism is slower (second time scale) and more energy‐consuming than that of LGICs, but long lasting and much more versatile. Due to this versatility, GPCRs are the most popular targets for drugs in clinical use.[1](#med21552-bib-0001){ref-type="ref"}, [2](#med21552-bib-0002){ref-type="ref"} GPCR‐target drugs or ligands, can be described as agonists or antagonists depending on their effect on the receptor. Agonist drugs can be broadly defined as substances that act like the endogenous neurotransmitter (by binding to the receptor and inducing a physiological response), whereas antagonist drugs bind but do not induce a response and can block the action of the endogenous neurotransmitter.

![Simplified signaling mechanisms of ligand‐gated ion channels (A) and G‐protein‐coupled receptors (B). If an agonist (represented by a triangle) binds to a channel, the channel opens and ions (represented by small diamonds) can enter the cell. If the agonist binds to a receptor, the G‐protein (represented by an ellipse) dissociates from the receptor complex and activates specific effector proteins](MED-39-1014-g001){#med21552-fig-0001}

In vitro studies in membrane homogenates from cultured cells or isolated tissues have shown that in a single population of GPCRs to which antagonist drugs have a single affinity, agonist drugs recognize two distinct receptor subpopulations: one for which they have high affinity and one for which they have low affinity. The existence of a receptor subpopulation that possesses high‐affinity toward the agonists (dubbed "high‐affinity state," R~high~) has been demonstrated for numerous neurotransmitter GPCRs including dopaminergic,[3](#med21552-bib-0003){ref-type="ref"}, [4](#med21552-bib-0004){ref-type="ref"} serotonergic,[5](#med21552-bib-0005){ref-type="ref"}, [6](#med21552-bib-0006){ref-type="ref"}, [7](#med21552-bib-0007){ref-type="ref"} muscarinic,[8](#med21552-bib-0008){ref-type="ref"} and opioid receptors.[9](#med21552-bib-0009){ref-type="ref"} The high‐affinity state is commonly thought to be composed of receptor molecules bound to G‐proteins. A crystal structure of such an activated state of the receptor, in complex with the G‐protein, was first obtained in 2011.[10](#med21552-bib-0010){ref-type="ref"}

The relationship between G‐protein coupling and high‐affinity toward the agonist gave rise to a hypothesis that the relative abundance of R~high~ may characterize the responsiveness of the synaptic signaling machinery to agonist levels. Indeed, alterations of the fraction of receptors configured in the high‐affinity state, as measured in membrane homogenates, were found in pathological states associated with dysregulation of neurotransmission. For instance, the relative abundance of the high‐affinity state of µ‐opioid receptors was decreased in guinea pigs after chronic morphine treatment,[11](#med21552-bib-0011){ref-type="ref"} while the high‐affinity state of muscarinic M~1~ receptors was downregulated in Alzheimer\'s disease.[12](#med21552-bib-0012){ref-type="ref"}, [13](#med21552-bib-0013){ref-type="ref"} Upregulation of the high‐affinity state of dopamine D~2~ receptors has been reported in several animal models of psychosis.[14](#med21552-bib-0014){ref-type="ref"}, [15](#med21552-bib-0015){ref-type="ref"}

Assessing the availability of R~high~ may, therefore, provide more valuable information about the state of neurotransmission in vivo than assessing the availability of total receptors. Given that agonists preferentially bind to R~high~, this hypothesis spurred the development of agonist PET tracers and their use for neuroreceptor imaging.

In this study we will review and discuss the molecular basis of the high‐affinity state, inherent advantages and shortcomings of agonist PET tracers stemming from their preferential binding to the high‐affinity state, agonist PET tracers currently available for receptor imaging, experimental methods used for the imaging of high‐affinity state in vivo, and evidence collected with these methods.

2. NATURE OF THE HIGH‐AFFINITY STATE OF GPCRS {#med21552-sec-0020}
=============================================

2.1. G‐protein‐dependent high‐affinity state {#med21552-sec-0030}
--------------------------------------------

The canonical view of the nature of the high‐affinity state is based on the so‐called ternary complex model of G‐protein signaling which originates from the studies of agonist binding to β‐adrenergic receptors in membrane homogenates.[16](#med21552-bib-0016){ref-type="ref"}, [17](#med21552-bib-0017){ref-type="ref"} This model claims that a "ternary" complex must form to launch the G‐protein signaling cascade, consisting of agonist, receptor, and G‐protein. Positive cooperativity between receptor‐agonist and receptor‐G‐protein binding creates the separation of the total receptor population into high‐ and low‐affinity states. For the agonist, receptors complexed with G‐proteins form the high‐affinity state, whereas free receptor molecules represent the low‐affinity state. Indeed, the preference of ligands for the G‐protein‐bound high‐affinity state was found to correlate with their intrinsic activity.[18](#med21552-bib-0018){ref-type="ref"}, [19](#med21552-bib-0019){ref-type="ref"}, [20](#med21552-bib-0020){ref-type="ref"}

Several newer and more sophisticated versions of the ternary complex model have been developed to account for pharmacological phenomena such as constitutive activity (presence of baseline signaling in the absence of agonists) and inverse agonism (existence of ligands that decrease rather than increase the level of signaling relative to baseline). These models imply the existence of more than two receptor species with different affinities for the agonist but the main premise remains the same: G‐protein binding is the main factor that determines the receptor\'s affinity toward the agonist.[21](#med21552-bib-0021){ref-type="ref"}, [22](#med21552-bib-0022){ref-type="ref"}

An important feature of the G‐protein‐dependent high‐affinity state is its sensitivity to guanosine triphosphate (GTP). Indeed, the high‐affinity state of GPCRs detected in membrane homogenates usually disappears upon GTP addition.[3](#med21552-bib-0003){ref-type="ref"}, [4](#med21552-bib-0004){ref-type="ref"}, [5](#med21552-bib-0005){ref-type="ref"}, [6](#med21552-bib-0006){ref-type="ref"}, [7](#med21552-bib-0007){ref-type="ref"}, [8](#med21552-bib-0008){ref-type="ref"}, [9](#med21552-bib-0009){ref-type="ref"} The reason for this is that the canonical G‐protein signaling cascade involves a so‐called GTP cycle (Figure [2](#med21552-fig-0002){ref-type="fig"}). G‐proteins are heterotrimers and one of their subunits, Gα, has a binding site for guanosine nucleotide (this gives G‐proteins their name). In an inactive G‐protein, this site is occupied by guanosine diphosphate (GDP). Upon G‐protein activation by an agonist‐bound receptor, GDP is replaced by GTP from the cytoplasm, which leads to the dissociation of Gα‐subunit from the Gβ and Gγ subunits (together referred to as Gβγ). The G‐protein splits into two parts, which then activate downstream effectors. If the G‐protein uncouples from the receptor, the receptor quickly returns to its inactive "low‐affinity" state.[23](#med21552-bib-0023){ref-type="ref"} Eventual hydrolysis of GTP to GDP in the Gα subunit lets the G‐protein reassemble and bind to the receptor again, which closes the cycle.[24](#med21552-bib-0024){ref-type="ref"}

![GPCR activation (left circuit, open arrows) and GTP cycle (right circuit, solid arrows). As in Figure [1](#med21552-fig-0001){ref-type="fig"}, the agonist is represented by a triangle, the G‐protein by an ellipse and the receptor by a sinusoid line. The center of the figure shows the "ternary complex" consisting of agonist, receptor and G‐protein. GPCR, G‐protein‐coupled receptor; GTP, guanosine triphosphate](MED-39-1014-g002){#med21552-fig-0002}

Therefore, the GTP cycle acts as a negative‐feedback loop, promoting G‐protein decoupling from the receptors and their (temporary) conversion into the low‐affinity state after agonist binding. Excess GTP shifts the equilibrium toward complete dissociation of G‐proteins from the receptors.

2.2. Oligomerization‐dependent high‐affinity state {#med21552-sec-0040}
--------------------------------------------------

The growing amount of evidence on GPCR oligomerization in cultured cells and living tissues [25](#med21552-bib-0025){ref-type="ref"} and on the pharmacological relevance of such oligomerization (see Ferre et al[26](#med21552-bib-0026){ref-type="ref"} for review) has given rise to the concept of oligomerization‐dependent high‐affinity state. When the agonist interacts with a receptor oligomer, occupying and activating a single receptor unit within it, conformational changes in this receptor influence the conformation of other receptors within the same oligomer and decrease their affinity for other agonist molecules (Figure [3](#med21552-fig-0003){ref-type="fig"}). In other words, separation into high‐ and low‐affinity states is caused by negative cooperativity effects of the agonist binding to oligomerized receptors.[27](#med21552-bib-0027){ref-type="ref"}

![Oligomerization‐dependent high‐affinity state. In this schematic representation, the receptors are drawn as homodimers. Most higher order G‐protein‐coupled receptor complexes are homodimers, heterodimers or tetramers consisting of two different homodimers. The high‐affinity state of the receptor is pictured as a sinusoid, the low‐affinity state as a compressed sinusoid, and the agonist as a triangle is pictured as a compressed sinusoid and the agonist as a triangle](MED-39-1014-g003){#med21552-fig-0003}

Receptor oligomerization is arguably mainly relevant for the explanation of the interplay between signaling pathways of different receptors[26](#med21552-bib-0026){ref-type="ref"}: interaction between oligomer subunits is conceptually simpler than interference of downstream cascades. However, among data from radioligand binding studies there are also some results that could be explained better by oligomerization than by G‐protein coupling, such as: (i) GTP‐insensitive high‐affinity agonist binding to dopamine D~3~ and serotonin 5‐HT~2A~ receptors,[28](#med21552-bib-0028){ref-type="ref"}, [29](#med21552-bib-0029){ref-type="ref"} (ii) detection of high‐ and low‐affinity states of adenosine A~2A~ receptors by antagonist ligands, [30](#med21552-bib-0030){ref-type="ref"} and (iii) detection of several (more than two) binding sites with different affinities to agonists in the muscarinic M~2~ receptor population.[31](#med21552-bib-0031){ref-type="ref"}

If there is cooperativity between receptor‐agonist and receptor‐receptor interaction, agonist binding might influence the degree of receptor oligomerization. Some studies indeed report such phenomena[32](#med21552-bib-0032){ref-type="ref"}, [33](#med21552-bib-0033){ref-type="ref"} but, in general, experimental data on the relationship between ligand binding and oligomerization are contradictory both in terms of whether ligand binding really promotes formation or dissociation of oligomers and whether this action is correlated with intrinsic activity (see Cottet et al[34](#med21552-bib-0034){ref-type="ref"}, [35](#med21552-bib-0035){ref-type="ref"} for review).

2.3. Influence of agonist binding on the high‐affinity state {#med21552-sec-0050}
------------------------------------------------------------

In both G‐protein coupling and oligomerization‐dependent models of high‐affinity state, agonist binding to the receptor influences receptor interaction with other molecules and thus can alter the relative abundance of the high‐affinity state.

### 2.3.1. G‐protein‐dependent high‐affinity state {#med21552-sec-0060}

Under conditions where no feedback loops are present, as is the case with in vitro binding studies with nonliving material like membrane homogenates and tissue slices, the relationship between agonist concentration and percentage of receptors in the high‐affinity state at equilibrium is straightforward. In the absence of GTP, agonist binding can only increase G‐protein recruitment. Therefore, increasing agonist concentration will make the percentage of receptors in the "G‐protein‐dependent" high‐affinity state grow from some "floor" value (see Section [2.5](#med21552-sec-0090){ref-type="sec"}) to the "ceiling" value determined by receptor‐G‐protein stoichiometry in the system (100% if the number of available G‐proteins is greater than or equal to the number of receptors). On the other hand, in the presence of excess GTP and negligible GTP hydrolysis, all G‐proteins activated by agonist‐bound receptors will be dissociated and uncoupled from the receptors, so at any agonist concentration, there will be no discernible high‐affinity state.

In living cells and tissues, however, the GTP cycle plays the role of a negative‐feedback loop, which counteracts excess high‐to‐low or low‐to‐high conversion of affinity states caused by the agonist. Depending on the combination of concentrations and kinetic rates, either G‐protein‐recruiting or G‐protein‐dissociating effects of an agonist can become dominant. Indeed, mathematical simulations of GPCR signaling have demonstrated the possibility of both agonist‐induced increase and decrease in the relative abundance of the G‐protein‐dependent high‐affinity state.[22](#med21552-bib-0022){ref-type="ref"}

### 2.3.2. Oligomerization‐dependent high‐affinity state {#med21552-sec-0070}

Negative cooperativity in agonist binding to oligomerized receptors implies that increasing agonist concentration will bring more and more receptors into "low‐affinity state." The percentage of receptors in the high‐affinity state, equal to 100% in the absence of agonist, will decrease to 100%/*N* (*N* is the average number of receptors per oligomer) when the agonist occupies one receptor unit in each oligomer, converting all the other units to low‐affinity state. When agonist concentration raises so high that agonists start to occupy receptors in the low‐affinity state, the relative abundance of the high‐affinity state will fall even lower. There are no well described and widely accepted feedback loops for the oligomerization‐dependent model of the high‐affinity state.

2.4. Agonist‐induced receptor internalization {#med21552-sec-0080}
---------------------------------------------

Activation of GPCRs by agonists promotes not only G‐protein binding to them but also their phosphorylation by G‐protein‐coupled receptor kinase (GRK) and internalization mediated by β‐arrestins.[36](#med21552-bib-0036){ref-type="ref"} This provides an extra pathway through which the agonist can influence the relative abundance of the high‐affinity state. Internalized receptors are decoupled from G‐proteins (coupled to β‐arrestins instead) and removed from the cell surface to intracellular compartments, where the ionic environment and pH value can be different from extracellular conditions. This makes internalized receptors less accessible (especially for hydrophilic radioligands) and possibly also alters their affinity toward their ligands.

In vitro, β‐arrestin recruitment can happen within minutes.[37](#med21552-bib-0037){ref-type="ref"}, [38](#med21552-bib-0038){ref-type="ref"} Internalization of dopamine D~2/3~ receptors was observed within the same time frame in vivo and was shown to be dose‐dependent.[39](#med21552-bib-0039){ref-type="ref"} Although it is not yet clear whether internalization mainly happens to receptors in the low‐ or high‐affinity state,[40](#med21552-bib-0040){ref-type="ref"}, [41](#med21552-bib-0041){ref-type="ref"} internalized dopamine D~2/3~ receptors on intact cells and µ‐opioid receptors incubated in a buffer imitating endosomal medium were shown to have decreased affinities toward their ligands.[42](#med21552-bib-0042){ref-type="ref"}, [43](#med21552-bib-0043){ref-type="ref"}

Therefore, high concentrations of an agonist can promote receptor internalization and change the number and relative abundances of receptor subpopulations with different affinities toward imaging radioligands. On the other hand, in internalization‐deficient β‐arrestin knockout mice, baseline binding of dopamine D~2/3~ agonist and antagonist tracers was the same as in wild‐type controls.[44](#med21552-bib-0044){ref-type="ref"} This may mean that at basal neurotransmitter levels there already is an equilibrium between neurotransmitter‐induced receptor internalization and recycling.

2.5. Relative abundance of high‐affinity state in the absence of the agonist {#med21552-sec-0090}
----------------------------------------------------------------------------

The oligomerization‐dependent model of the high‐affinity state implies that this is the state in which all receptors are configured in the absence of the agonist.

For the G‐protein‐dependent high‐affinity state, its baseline relative abundance, that is, the degree to which G‐proteins interact with the receptors in the absence of agonist is a matter of debate.[45](#med21552-bib-0045){ref-type="ref"}, [46](#med21552-bib-0046){ref-type="ref"} One extreme view, called collision coupling (Figure [4](#med21552-fig-0004){ref-type="fig"}A), states that in living cells G‐proteins are not normally bound to the receptors but instead interact with them transiently when receptors become activated.[47](#med21552-bib-0047){ref-type="ref"} Another extreme view (Figure [4](#med21552-fig-0004){ref-type="fig"}B) states that G‐proteins are always bound (precoupled) to the receptors and do not decouple even after activation, which happens through structural rearrangement of the G‐protein rather than through dissociation.[48](#med21552-bib-0048){ref-type="ref"}, [49](#med21552-bib-0049){ref-type="ref"}, [50](#med21552-bib-0050){ref-type="ref"}

![Two extreme modes of receptor‐G‐protein interaction. The agonist is represented by a triangle, the receptor by a sinusoid line and the G‐protein by an ellipse. A, In the collision coupling model, G‐proteins do not stably interact with receptors but agonist action on the receptor promotes G‐protein recruitment to and activation by the receptors, which results in the dissociation of G‐proteins. B, In the precoupling model, G‐proteins are stably bound to the receptors and rearrange their structures upon activation instead of dissociating. GDP, guanosine diphosphate; GTP, guanosine triphosphate](MED-39-1014-g004){#med21552-fig-0004}

On the one hand, collision coupling provides a straightforward interpretation of differences in intrinsic activities of the agonists: agonist efficacy is related to the number of different G‐proteins that an agonist‐bound receptor can bind and activate per unit of time. Decoupling of G‐proteins from the receptors upon activation explains the disappearance of the high‐affinity state upon GTP addition in membrane homogenates. On the other hand, receptors and G‐proteins are known to be coisolated by immunoprecipitation and bioluminescence resonance energy transfer/fluorescence resonance energy transfer (BRET/FRET) experiments with mutated proteins incorporating fluorescent or bioluminescent probe demonstrate close contact between receptors and G‐proteins in the absence of agonists.[45](#med21552-bib-0045){ref-type="ref"} Moreover, in BRET studies with α~2~ adrenergic and δ‐opioid receptors, these receptors were found to interact with G‐proteins both before and after activation by agonist.[49](#med21552-bib-0049){ref-type="ref"}, [50](#med21552-bib-0050){ref-type="ref"}

A middle ground between the extreme views is, of course, possible, where some G‐proteins are bound to receptors at baseline but decoupled upon activation, or where G‐proteins are uncoupled at baseline but become bound to receptors upon activation. Moreover, BRET and FRET experiments image the whole population of the receptors, so constant presence of a RET signal, while showing that a fraction of receptors are engaged with G‐proteins, does not exclude the possibility of a rapid turnover of G‐proteins with which these receptors interact.

2.6. Summary {#med21552-sec-0100}
------------

The existence of high‐ and low‐affinity states of GPCRs is commonly thought to be due to receptor interaction with G‐proteins. Being a part of the canonical GPCR signaling cascade, the receptor‐G‐protein coupling is directly related to the pharmacological activity of the agonists.

GPCR oligomerization (both homo and hetero), with negative cooperativity in agonist binding within the oligomer, can be an alternative mechanism leading to the formation of receptor subpopulations with different affinities for the agonist. It is plausible that at least for some GPCRs, oligomerization can contribute to the splitting of receptors into high‐ and low‐affinity states instead of, or in addition to, G‐protein coupling.

Both models of high‐affinity state imply that agonists preferentially bind to receptors that are almost ready to launch the signaling cascade, although in the oligomerization model it is so just because agonist binding makes unoccupied receptors "less ready." Moreover, agonist binding can influence the relative abundance of the high‐affinity state, potentially promoting its formation or disintegration and launching receptor internalization in intact cells and living tissues. Such influence is most directly demonstrated for the G‐protein‐dependent model of the high‐affinity state.

3. EXPECTED ADVANTAGES AND DISADVANTAGES OF AGONIST TRACERS RELATIVE TO ANTAGONIST TRACERS {#med21552-sec-0110}
==========================================================================================

From the notion that agonists preferentially bind to a high‐affinity functional subset of receptors one can logically infer a number of applications in which agonist tracers should be superior, in theory, to antagonist tracers. Note that proposed advantages of agonist tracers mentioned below hold independently of whether the high‐affinity state is G‐protein‐dependent or oligomerization‐dependent.

3.1. Applications where agonist tracers have comparative advantage over antagonist tracers {#med21552-sec-0120}
------------------------------------------------------------------------------------------

### 3.1.1. Measurement of synaptic neurotransmission {#med21552-sec-0130}

An endogenous neurotransmitter is an agonist by definition, so it competes with the agonist tracer for the same subset of receptors---receptors configured in high‐affinity state---while an antagonist tracer also binds to receptors in the low‐affinity state that are "ignored" by the neurotransmitter except at very high concentrations. This means that a change in the concentration of neurotransmitter of a given magnitude will lead to greater change in agonist tracer binding compared with antagonist tracer binding (Figure [5](#med21552-fig-0005){ref-type="fig"}).

![Greater sensitivity of agonist tracers to displacement ("challenge") by neurotransmitter. Agonist tracers primarily bind to the receptors configured in the high‐affinity state (ie, coupled to G‐proteins), as do neurotransmitters. Therefore, the same change in receptor occupancy by the neurotransmitter displaces a greater fraction of bound agonist tracer (A) than of bound antagonist tracer (B). In this schematic diagram, the endogenous neurotransmitter is pictured as a circle, the agonist ligand as a triangle, the antagonist ligand as a diamond, the G‐protein as an ellipse, and the receptor as a sinusoid line](MED-39-1014-g005){#med21552-fig-0005}

For some receptor families (eg, serotonin 5‐HT~1A~ and 5‐HT~2A~ receptors), all available antagonist tracers appear to be insensitive to alterations of endogenous neurotransmitter levels.[51](#med21552-bib-0051){ref-type="ref"} As agonist tracers are supposed to be more sensitive than antagonist tracers to endogenous neurotransmitter competition, developing agonist ligands is considered a promising way to obtain a tool for the measurement of synaptic neurotransmission via these receptors.[52](#med21552-bib-0052){ref-type="ref"}

### 3.1.2. Studies of (pathological) alterations in receptor availability {#med21552-sec-0140}

In Section [1](#med21552-sec-0010){ref-type="sec"}, a few examples were given of how alterations of the percentage of receptors configured in the high‐affinity state can accompany the disease. Since the high‐affinity state is the active form of the receptor involved in signaling and may be primarily affected by the disease, the abundance of the high‐affinity state could be a more meaningful biomarker than the total receptor density. Agonist tracers should then be a convenient tool for pinpointing alterations of the availability of receptors configured in the high‐affinity state in disease.

The results of some in vitro experiments with agonist and antagonist radioligands have supported the hypothesis that agonist tracers are superior to antagonists in detecting pathological changes in neuroreceptor availability. In vitro binding of the 5‐HT~1A~ agonists \[^18^F\]F15599 and \[^18^F\]F13640 but not of the antagonist \[^18^F\]MPPF, in postmortem brain sections of Alzheimer\'s patients was decreased compared with control brains.[53](#med21552-bib-0053){ref-type="ref"}, [54](#med21552-bib-0054){ref-type="ref"} In unilateral 6‐hydroxydopamine‐induced lesions of the rat brain (exhibiting dopaminergic neurodegeneration similar to Parkinson\'s disease in humans, where upregulation of R~high~ is hypothesized), the ex vivo binding of dopamine D~2/3~ agonist \[^3^H\]NPA was changed to a greater extent than the in vitro binding of D~2/3~ antagonist \[^3^H\]raclopride.[55](#med21552-bib-0055){ref-type="ref"}

### 3.1.3. Measurement of agonist drug occupancy {#med21552-sec-0150}

Many drugs owe their effect to their agonist activity at one or more kinds of receptors. For instance, many antiparkinsonian drugs are D~2/3~ agonists[56](#med21552-bib-0056){ref-type="ref"}; muscarinic receptor agonists like milameline were tried as treatment of Alzheimer\'s disease[57](#med21552-bib-0057){ref-type="ref"}; the mechanism of action of antipsychotics may include not only D~2/3~ antagonism but also 5‐HT~1A~‐agonism[58](#med21552-bib-0058){ref-type="ref"}, [59](#med21552-bib-0059){ref-type="ref"}; the active metabolite of clozapine (also an atypical antipsychotic) acts as an agonist at muscarinic M~1~ receptors[60](#med21552-bib-0060){ref-type="ref"}; opiate agonists are widely used as analgesics or antitussives and for treating diarrhea and opiate abuse.[61](#med21552-bib-0061){ref-type="ref"}

Increased sensitivity of agonist tracers to displacement by agonist drugs may be an advantage in occupancy studies: the opioid receptor antagonist \[^11^C\]diprenorphine failed to detect receptor occupancy by clinically relevant doses of opioid agonists.[62](#med21552-bib-0062){ref-type="ref"}, [63](#med21552-bib-0063){ref-type="ref"} However, no studies have so far been published, where the sensitivity of an agonist and an antagonist opioid receptor tracer with equal subtype‐selectivity to displacement by an agonist drug was compared head‐to‐head.

Agonist tracers can also complement antagonist tracers in the investigations of the affinity‐state preference of new drugs. The sensitivities of agonist and antagonist tracers to the displacement by the drug can be compared: drugs preferring the high‐affinity state will displace the agonist tracer more readily, while drugs not distinguishing between affinity states will show no difference in displacement efficacy. Two studies attempting this approach have been published[64](#med21552-bib-0064){ref-type="ref"}, [65](#med21552-bib-0065){ref-type="ref"} but both reported equal displacement of agonist and antagonist tracers by the drug, which can be interpreted in two ways: either the tested drugs were ideal antagonists or the hypothesis of greater agonist tracer displacement by agonist drug does not hold.

3.2. Intrinsic shortcomings of agonist tracers {#med21552-sec-0160}
----------------------------------------------

Though the preference for the high‐affinity state makes agonist tracers potentially superior to antagonists in certain imaging applications, it also results in a number of specific difficulties associated with the development and use of agonist tracers.

### 3.2.1. Lower signal‐to‐noise ratios {#med21552-sec-0170}

The signal‐to‐noise ratio of a PET tracer is proportional to the density of receptors the tracer binds to in the brain (*B* ~avail~) and to the tracer\'s affinity toward these receptors (1/*K* ~d~). The density of receptors configured in the high‐affinity state (and thus recognized by agonist tracers) is by definition lower than the total receptor density.

Moreover, estimates of agonist affinity toward the high‐affinity state, acquired in membrane homogenates in vitro, may be systematically higher than the actual affinity in vivo. The reason why it may be so is the negative‐feedback between agonist‐receptor and receptor‐G‐protein binding in the GTP cycle (see Section [2.3](#med21552-sec-0050){ref-type="sec"}), which is part of the G‐protein‐dependent model of the high‐affinity state. Indeed, GTP depletion was shown to increase the affinity of agonist but not antagonist ligands to opioid receptors in cultured cells.[66](#med21552-bib-0066){ref-type="ref"} Therefore, affinity and nonspecific binding requirements for agonist tracers are stricter than for antagonists.

### 3.2.2. Greater likelihood of unwanted pharmacological effects {#med21552-sec-0180}

As agonist tracers preferentially bind to the functional subpopulation of the receptors, they may induce significant physiological responses at a rather low dose, which can distort the experimental results and cause discomfort to the patients.

Indeed, staying below the pharmacological dose range is a concern in opioid receptor imaging with agonist tracers.[67](#med21552-bib-0067){ref-type="ref"}, [68](#med21552-bib-0068){ref-type="ref"}, [69](#med21552-bib-0069){ref-type="ref"} It was also reported as a potential concern in serotonin 5‐HT~1A~ receptor imaging with the agonist \[^11^C\]CUMI‐101,[70](#med21552-bib-0070){ref-type="ref"} even though first tests of the same compound in humans showed no adverse effects.[71](#med21552-bib-0071){ref-type="ref"} Exceeding the pharmacological threshold is especially easy with tracers with low specific radioactivity and a related high injected mass of the radioligand. The risk of low specific radioactivity is increased when labeling chemistry is complex. For instance, the dopamine D~2/3~ receptor agonist \[^11^C\](+)PHNO was originally labeled via a four‐step route, resulting in a relatively low specific radioactivity.[72](#med21552-bib-0072){ref-type="ref"} As a consequence, a high incidence of nausea (emesis is a typical effect of D~2~ agonism) was reported in patients injected with \[^11^C\](+)PHNO,[73](#med21552-bib-0073){ref-type="ref"} and it was later found that \[^11^C\](+)PHNO human PET studies had frequently been performed under nontracer conditions.[74](#med21552-bib-0074){ref-type="ref"}

4. EXISTING PET AGONIST TRACERS FOR GPCR IMAGING IN THE CENTRAL NERVOUS SYSTEM {#med21552-sec-0190}
==============================================================================

The greatest number of agonist PET tracers has been developed for the imaging of dopamine D~2/3~ receptors (see [75](#med21552-bib-0075){ref-type="ref"} for a review). Tracer development efforts in the last two decades have yielded a number of agonist radioligands for other receptors as well. The most promising agonist tracers developed for PET imaging of neuroreceptors are presented in Table [1](#med21552-tbl-0001){ref-type="table"}, Figure [6](#med21552-fig-0006){ref-type="fig"} and Figure [7](#med21552-fig-0007){ref-type="fig"}.

###### 

Agonist tracers developed for the imaging of high‐affinity state of neuroreceptors

  Receptors                   Tracer names                                             In vitro evaluation                                                                                   In vivo evaluation                                                                                                                           Remarks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  --------------------------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dopamine D~1/5~             (*S*)(+)\[^11^C\]SKF82957                                ND                                                                                                    COMP+ GTPdis+[76](#med21552-bib-0076){ref-type="ref"}                                                                                        Rats[77](#med21552-bib-0077){ref-type="ref"}, [78](#med21552-bib-0078){ref-type="ref"}, [79](#med21552-bib-0079){ref-type="ref"}                                                                                                                                   ND                                                                                                                              ND                                                  ND                                                                                                                                                 Rats--[77](#med21552-bib-0077){ref-type="ref"}                                                                                                                                                                                                                                                                                Lipophilic metabolites in brain tissue
  (*S*)\[^11^C\]NNC 01‐0259   MESS+[80](#med21552-bib-0080){ref-type="ref"}            ND                                                                                                    ND                                                                                                                                           [81](#med21552-bib-0081){ref-type="ref"}, [82](#med21552-bib-0082){ref-type="ref"}, [83](#med21552-bib-0083){ref-type="ref"}                                                                                                                                       ND                                                                                                                              ND                                                  Primates--[80](#med21552-bib-0080){ref-type="ref"}                                                                                                 Lipophilic metabolites in brain tissue                                                                                                                                                                                                                                                                                        
  Dopamine D~2/3~             \[^11^C\]PHNO                                            ND                                                                                                    GTPdis+[84](#med21552-bib-0084){ref-type="ref"} COMP+[85](#med21552-bib-0085){ref-type="ref"} SAT−[86](#med21552-bib-0086){ref-type="ref"}   Rats[72](#med21552-bib-0072){ref-type="ref"}, [87](#med21552-bib-0087){ref-type="ref"}, [88](#med21552-bib-0088){ref-type="ref"}                                                                                                                                   [89](#med21552-bib-0089){ref-type="ref"}                                                                                        Cats[90](#med21552-bib-0090){ref-type="ref"}        [91](#med21552-bib-0091){ref-type="ref"} (first)                                                                                                   Rats+[72](#med21552-bib-0072){ref-type="ref"}, [87](#med21552-bib-0087){ref-type="ref"}, [88](#med21552-bib-0088){ref-type="ref"} cats+[90](#med21552-bib-0090){ref-type="ref"} primates+[92](#med21552-bib-0092){ref-type="ref"} humans+[93](#med21552-bib-0093){ref-type="ref"}, [94](#med21552-bib-0094){ref-type="ref"}   Now primarily used as D~3~‐selective tracer[95](#med21552-bib-0095){ref-type="ref"} derivation of ^18^F‐version unsuccessful[96](#med21552-bib-0096){ref-type="ref"}
  \[^11^C\]NPA                ND                                                       COMP+[56](#med21552-bib-0056){ref-type="ref"}, [85](#med21552-bib-0085){ref-type="ref"}               Rats[97](#med21552-bib-0097){ref-type="ref"}                                                                                                 [97](#med21552-bib-0097){ref-type="ref"}, [98](#med21552-bib-0098){ref-type="ref"}, [99](#med21552-bib-0099){ref-type="ref"}                                                                                                                                       Cats[90](#med21552-bib-0090){ref-type="ref"} pigs[100](#med21552-bib-0100){ref-type="ref"}                                      [101](#med21552-bib-0101){ref-type="ref"} (first)   Cats+[90](#med21552-bib-0090){ref-type="ref"} primates+[99](#med21552-bib-0099){ref-type="ref"} humans+[102](#med21552-bib-0102){ref-type="ref"}   Relatively difficult radiosynthesis                                                                                                                                                                                                                                                                                           
  \[^11^C\]MNPA               ND                                                       COMP+[28](#med21552-bib-0028){ref-type="ref"} SAT−[86](#med21552-bib-0086){ref-type="ref"}            Mice[44](#med21552-bib-0044){ref-type="ref"}, [103](#med21552-bib-0103){ref-type="ref"} rats[104](#med21552-bib-0104){ref-type="ref"}        [105](#med21552-bib-0105){ref-type="ref"}, [106](#med21552-bib-0106){ref-type="ref"}, [107](#med21552-bib-0107){ref-type="ref"}, [108](#med21552-bib-0108){ref-type="ref"}, [109](#med21552-bib-0109){ref-type="ref"}, [110](#med21552-bib-0110){ref-type="ref"}   ND                                                                                                                              [111](#med21552-bib-0111){ref-type="ref"} (first)   Rats+[104](#med21552-bib-0104){ref-type="ref"} mice+[44](#med21552-bib-0044){ref-type="ref"} primates+[109](#med21552-bib-0109){ref-type="ref"}    Lowest BP~ND~ (see Section 5.1.1) among D~2/3~ tracers used in humans                                                                                                                                                                                                                                                         
  \[^18^F\]MCL‐524            ND                                                       COMP+[112](#med21552-bib-0112){ref-type="ref"}                                                        ND                                                                                                                                           [113](#med21552-bib-0113){ref-type="ref"}                                                                                                                                                                                                                          ND                                                                                                                              ND                                                  Primates+[113](#med21552-bib-0113){ref-type="ref"}                                                                                                 Structurally related to NPA and MNPA                                                                                                                                                                                                                                                                                          
  Dopamine D~2~               \[^11^C\]SV‐III‐130                                      MESS+[114](#med21552-bib-0114){ref-type="ref"}                                                        ND                                                                                                                                           ND                                                                                                                                                                                                                                                                 [114](#med21552-bib-0114){ref-type="ref"}                                                                                       ND                                                  ND                                                                                                                                                 Primates+[114](#med21552-bib-0114){ref-type="ref"}                                                                                                                                                                                                                                                                            Possible 5‐HT~1A~ binding
  Dopamine D~3~               \[^18^F\]LS‐3‐134                                        MESS+[115](#med21552-bib-0115){ref-type="ref"}                                                        COMP−[116](#med21552-bib-0116){ref-type="ref"}                                                                                               ND                                                                                                                                                                                                                                                                 [115](#med21552-bib-0115){ref-type="ref"}                                                                                       ND                                                  ND                                                                                                                                                 Primates+[115](#med21552-bib-0115){ref-type="ref"}                                                                                                                                                                                                                                                                            Specific binding seen only after dopamine depletion
  \[^18^F\]7‐OH‐FHXPAT        ND                                                       GTPdis+[117](#med21552-bib-0117){ref-type="ref"}                                                      mice, rats[117](#med21552-bib-0117){ref-type="ref"}                                                                                          ND                                                                                                                                                                                                                                                                 ND                                                                                                                              ND                                                  ND                                                                                                                                                 D~3~‐over‐D~2~ selectivity not fully characterized                                                                                                                                                                                                                                                                            
  Serotonin 5‐HT~1A~          \[^11^C\]CUMI‐101                                        GTPrec-- [118](#med21552-bib-0118){ref-type="ref"} GTPrec±[119](#med21552-bib-0119){ref-type="ref"}   ND                                                                                                                                           ND                                                                                                                                                                                                                                                                 [70](#med21552-bib-0070){ref-type="ref"}, [120](#med21552-bib-0120){ref-type="ref"}                                             ND                                                  [71](#med21552-bib-0071){ref-type="ref"}, [121](#med21552-bib-0121){ref-type="ref"}                                                                Rodents−[122](#med21552-bib-0122){ref-type="ref"} primates+[123](#med21552-bib-0123){ref-type="ref"} humans−[124](#med21552-bib-0124){ref-type="ref"} humans±[125](#med21552-bib-0125){ref-type="ref"}                                                                                                                        Variable intrinsic activity [118](#med21552-bib-0118){ref-type="ref"}, [119](#med21552-bib-0119){ref-type="ref"}, [126](#med21552-bib-0126){ref-type="ref"} binds to adrenoceptors[118](#med21552-bib-0118){ref-type="ref"}, [126](#med21552-bib-0126){ref-type="ref"} derivation of ^18^F‐version successful[127](#med21552-bib-0127){ref-type="ref"}, [128](#med21552-bib-0128){ref-type="ref"}
  \[^18^F\]F13714             GTPrec+ MESS+[129](#med21552-bib-0129){ref-type="ref"}   GTPdis+[130](#med21552-bib-0130){ref-type="ref"}                                                      Rats[130](#med21552-bib-0130){ref-type="ref"}                                                                                                [131](#med21552-bib-0131){ref-type="ref"}                                                                                                                                                                                                                          Cats[130](#med21552-bib-0130){ref-type="ref"} marmosets[132](#med21552-bib-0132){ref-type="ref"}                                ND                                                  ND                                                                                                                                                 Specific binding is irreversible                                                                                                                                                                                                                                                                                              
  \[^18^F\]F13640             GTPrec+[133](#med21552-bib-0133){ref-type="ref"}         ND                                                                                                    Rats[134](#med21552-bib-0134){ref-type="ref"}                                                                                                [134](#med21552-bib-0134){ref-type="ref"}                                                                                                                                                                                                                          Cats[134](#med21552-bib-0134){ref-type="ref"}                                                                                   ND                                                  Rats+[134](#med21552-bib-0134){ref-type="ref"}                                                                                                     Slow, but reversible binding kinetics                                                                                                                                                                                                                                                                                         
  Serotonin 5‐HT~2A~          \[^11^C\]CIMBI‐36                                        MESS+[135](#med21552-bib-0135){ref-type="ref"}                                                        ND                                                                                                                                           Rats, mice (only safety)[136](#med21552-bib-0136){ref-type="ref"}                                                                                                                                                                                                  [137](#med21552-bib-0137){ref-type="ref"}                                                                                       Pigs[135](#med21552-bib-0135){ref-type="ref"}       [138](#med21552-bib-0138){ref-type="ref"}, [139](#med21552-bib-0139){ref-type="ref"}, [140](#med21552-bib-0140){ref-type="ref"}                    Pigs+[141](#med21552-bib-0141){ref-type="ref"} primates+[142](#med21552-bib-0142){ref-type="ref"} humans−[143](#med21552-bib-0143){ref-type="ref"}                                                                                                                                                                            Also binds to 5‐HT~2C~ [137](#med21552-bib-0137){ref-type="ref"} alternative ^11^C‐labeling positions compared [140](#med21552-bib-0140){ref-type="ref"} derivation of ^18^F‐version unsuccessful[144](#med21552-bib-0144){ref-type="ref"}
  κ‐Opioid                    \[^11^C\]GR103545 also known as (*R*)‐\[^11^C\]GR89696   PHYS+ (for κ)                                                                                         COMP±[145](#med21552-bib-0145){ref-type="ref"}                                                                                               Mice[146](#med21552-bib-0146){ref-type="ref"} (race‐mate)[147](#med21552-bib-0147){ref-type="ref"} (eutomer)                                                                                                                                                       [68](#med21552-bib-0068){ref-type="ref"}, [69](#med21552-bib-0069){ref-type="ref"}, [148](#med21552-bib-0148){ref-type="ref"}   ND                                                  [149](#med21552-bib-0149){ref-type="ref"}, [150](#med21552-bib-0150){ref-type="ref"}                                                               ND                                                                                                                                                                                                                                                                                                                            Competition assay shows biphasic binding but this may reflect different affinities for κ
  µ‐Opioid                    \[^11^C\]carfentanil (mu‐OR)                             PHYS+[151](#med21552-bib-0151){ref-type="ref"}                                                        ND                                                                                                                                           Mice[152](#med21552-bib-0152){ref-type="ref"} rats[43](#med21552-bib-0043){ref-type="ref"}                                                                                                                                                                         [153](#med21552-bib-0153){ref-type="ref"}                                                                                       ND                                                  [153](#med21552-bib-0153){ref-type="ref"}(first)                                                                                                   Rats+[43](#med21552-bib-0043){ref-type="ref"} humans+[154](#med21552-bib-0154){ref-type="ref"}, [155](#med21552-bib-0155){ref-type="ref"}, [156](#med21552-bib-0156){ref-type="ref"} humans−[157](#med21552-bib-0157){ref-type="ref"}                                                                                         Derivation of ^18^F‐version successful, no follow‐up[158](#med21552-bib-0158){ref-type="ref"}
  µ/κ‐Opioid                  \[^11^C\]PEO                                             GTPrec+[159](#med21552-bib-0159){ref-type="ref"}                                                      ND                                                                                                                                           Rats[159](#med21552-bib-0159){ref-type="ref"}                                                                                                                                                                                                                      ND                                                                                                                              ND                                                  ND                                                                                                                                                 ND                                                                                                                                                                                                                                                                                                                            Derivation of ^18^F‐version successful[160](#med21552-bib-0160){ref-type="ref"}, [161](#med21552-bib-0161){ref-type="ref"}
  Muscarinic M~1~             \[^11^C\]LSN3172176                                      GTPrec+[162](#med21552-bib-0162){ref-type="ref"}                                                      COMP−[162](#med21552-bib-0162){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                  [163](#med21552-bib-0163){ref-type="ref"}, [164](#med21552-bib-0164){ref-type="ref"}                                            ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Imperfect subtype‐selectivity
  \[^11^C\]AF‐150(*S*)        ND                                                       COMP+[20](#med21552-bib-0020){ref-type="ref"}                                                         Rats[165](#med21552-bib-0165){ref-type="ref"}, [166](#med21552-bib-0166){ref-type="ref"}                                                     ND                                                                                                                                                                                                                                                                 ND                                                                                                                              ND                                                  Rats±[166](#med21552-bib-0166){ref-type="ref"}                                                                                                     Low signal‐to‐noise ratios                                                                                                                                                                                                                                                                                                    
  Muscarinic M~2~             \[^18^F\]FP‐TZTP                                         PHYS+[167](#med21552-bib-0167){ref-type="ref"}                                                        ND                                                                                                                                           Mice[168](#med21552-bib-0168){ref-type="ref"} rats [169](#med21552-bib-0169){ref-type="ref"}, [170](#med21552-bib-0170){ref-type="ref"}, [171](#med21552-bib-0171){ref-type="ref"}                                                                                 [170](#med21552-bib-0170){ref-type="ref"}                                                                                       ND                                                  [172](#med21552-bib-0172){ref-type="ref"}(first)                                                                                                   Primates+[173](#med21552-bib-0173){ref-type="ref"}                                                                                                                                                                                                                                                                            ^11^C‐version created, no follow‐up[174](#med21552-bib-0174){ref-type="ref"}

Abbreviations GDP, guanosine diphosphate; GTP, guanosine triphosphate; ND, no data available.

Coding of experimental paradigms aiming to confirm agonism: MESS monitoring secondary messenger levels in functional assays in vitro*;* GTPrec monitoring GTP recruitment to G‐proteins in vitro; PHYS monitoring physiological or behavioral effects of the compound in vivo or ex vivo.

Works confirming functional agonism are cited only if the preference for R~high~ has not been directly confirmed.

Coding of experimental paradigms aiming to confirm preferential binding to R~high~: COMP obtaining a biphasic competition curve in vitro; SAT obtaining a biphasic saturation curve in vitro; GTPdis detecting the loss of specific binding upon GTP or GppNHp addition in vitro.

Coding of the outcomes of studies confirming sensitivity to endogenous neurotransmitter levels (and also agonism and R~high~ preference): +, positive outcome; −, negative outcome, ±, ambiguous results.

John Wiley & Sons, Ltd.

![Chemical structures of agonist radioligands for dopaminergic receptors (see also Table [1](#med21552-tbl-0001){ref-type="table"}). The position of the radionuclide in each molecule is indicated by an asterisk](MED-39-1014-g006){#med21552-fig-0006}

![Chemical structures of agonist radioligands for serotonin, opioid, and muscarinic receptors (see also Table [1](#med21552-tbl-0001){ref-type="table"}). \[^11^C\]PEO is not shown; its structure can be found in Van Waarde et al.[175](#med21552-bib-0175){ref-type="ref"} The position of the radionuclide in each molecule is indicated by an asterisk](MED-39-1014-g007){#med21552-fig-0007}

4.1. Definition and properties of an agonist tracer {#med21552-sec-0200}
---------------------------------------------------

An agonist tracer is usually defined as "a radiolabeled analog of a ligand with agonist activity." There are many ways to confirm and measure the degree of agonist activity: behavioral or ex vivo studies examining the physiological effect of the drug, functional in vitro assays measuring the levels of certain secondary messengers, or the recruiting of proteins involved in signaling cascades to the receptors.

Because the intrinsic activity of a ligand is known to be correlated with the ratio of its affinities to the high‐ and low‐affinity receptor states,[18](#med21552-bib-0018){ref-type="ref"}, [19](#med21552-bib-0019){ref-type="ref"} it seems evident that agonists will preferentially bind to the high‐affinity state. However, agonism does not necessarily imply preferential binding to receptor‐G‐protein complexes, since noncanonical signaling pathways do exist. One example is cariprazine, a drug which was recently labeled with carbon‐11 and evaluated as a dopamine D~2/3~ receptor PET tracer. This compound showed partial D~2/3~ agonist activity in secondary messenger assays but did not recruit G‐proteins in vitro.[176](#med21552-bib-0176){ref-type="ref"}, [177](#med21552-bib-0177){ref-type="ref"}, [178](#med21552-bib-0178){ref-type="ref"} Observations of G‐protein recruitment may also differ between in vitro setups. For instance, \[^11^C\]CUMI‐101, a tracer for serotonin 5‐HT~1A~ receptors, was defined as an agonist based on the \[^35^S\]GTPyS assay (indirect measurement of G‐protein recruiting to receptors) in membrane homogenates from cell cultures expressing recombinant human receptors but was later found to act as an antagonist when the same assay was done in primate and rat brain homogenates.[118](#med21552-bib-0118){ref-type="ref"}, [119](#med21552-bib-0119){ref-type="ref"}

Therefore, the most certain proof of the agonist radioligand\'s in vitro preference to the high‐affinity state is directly demonstrating that it recognizes high‐ and low‐affinity states of its receptor in natural tissue or in transfected cell culture. It is worth noting that for some agonist tracers, preferential in vitro binding to R~high~ was demonstrated only after the tracer had been evaluated in vivo (compare [105](#med21552-bib-0105){ref-type="ref"} and [28](#med21552-bib-0028){ref-type="ref"}), while for some other radioligands the capability to discern affinity states in vitro was not assessed at all.[80](#med21552-bib-0080){ref-type="ref"}, [135](#med21552-bib-0135){ref-type="ref"}

4.2. In vivo evaluation of a PET neuroreceptor tracer {#med21552-sec-0210}
-----------------------------------------------------

Characteristics desirable for a PET tracer for brain imaging include the ability to pass the blood‐brain‐barrier, a low degree of metabolism, a high contrast between target (specific) and nontarget (nonspecific) binding, and pharmacokinetics that can be reliably quantified from a 60 to 90 minute‐long PET scan (see [179](#med21552-bib-0179){ref-type="ref"}, [180](#med21552-bib-0180){ref-type="ref"}, [181](#med21552-bib-0181){ref-type="ref"} for review). An important aim in PET imaging is the measurement of synaptic neurotransmission. For this reason, neuroreceptor tracers are tested for the sensitivity of their binding to changes of endogenous neurotransmitter levels, and agonists are supposed to be more sensitive than antagonists.

Neuroreceptor tracers are usually evaluated in rodents or non‐human primates before being moved to human studies. In non‐human primates, one can investigate the binding of the tracers with high spatial detail using clinical PET cameras. Evaluation in rodents is cheaper and enables the use of more invasive methods but interspecies differences in rodent, primate, and human physiology can be a confounding factor. In addition, the small size of rodents forces the researchers to use dedicated nonclinical "micro‐PET" cameras and does not permit to reliably image minor brain structures. To strike the right balance between controllability of the experimental conditions and image quality, tracers are sometimes evaluated in (relatively) large mammals, such as cats or pigs.

4.3. Availability of agonist PET neuroreceptor tracers {#med21552-sec-0220}
------------------------------------------------------

Agonist PET tracers can be divided into three categories (see Table [1](#med21552-tbl-0001){ref-type="table"}). The first category includes radioligands that have reached the stage of in vivo evaluation in humans. The dopamine D~2/3~ ligands \[^11^C\](+)PHNO, \[^11^C\]NPA, and \[^11^C\]MNPA, the serotonin 5‐HT~1A~ ligand \[^11^C\]CUMI‐101, the serotonin 5‐HT~2A~ ligand \[^11^C\]CIMBI‐36, the κ‐opioid ligand \[^11^C\]GR103545, the µ‐opioid ligand \[^11^C\]carfentanil, and the muscarinic M~2~ receptor agonist \[^18^F\]FP‐TZTP fall into this category. The binding of most of these ligands has been shown to be sensitive to changes of endogenous neurotransmitter levels, although for \[^11^C\]CIMBI‐36 and \[^11^C\]CUMI‐101 the acquired results have been conflicting, and the sensitivity of \[^11^C\]GR103545 to endogenous opioids has not yet been evaluated. Many ligands from category one are used in PET imaging for other reasons than their agonist properties. \[^11^C\](+)PHNO, for example, is frequently selected as a tracer because it binds preferentially (though not selectively) to dopamine D~3~ receptors, and its preference for this subtype is higher than that of dopamine D~2/3~ antagonist ligands like \[^11^C\]raclopride.[95](#med21552-bib-0095){ref-type="ref"} \[^11^C\]CUMI‐101 is used in clinical studies,[182](#med21552-bib-0182){ref-type="ref"}, [183](#med21552-bib-0183){ref-type="ref"} not because of its ability to image the high‐affinity state of serotonin 5‐HT~1A~ receptors (which is actually under doubt---see below) but because of its high subtype‐selectivity and imaging contrast. \[^11^C\]carfentanil and \[^18^F\]TZTP are the only tracers available for µ‐opioid and muscarinic M~1~ receptors, so in their case, there are no antagonist tracers with which they could be compared head‐to‐head.

The second category contains radioligands that have not (yet) been tested in humans but have been evaluated in non‐human primates. The dopamine D~1/5~ ligand (*S*)\[^11^C\]NNC 01‐0259, the dopamine D~2/3~ ligand \[^18^F\]MCL‐524, the dopamine D~2~ ligand \[^11^C\]SV‐III‐130, the dopamine D~3~ ligand \[^18^F\]LS‐3‐134, the serotonin 5‐HT~1A~ ligands \[^18^F\]F13714 and \[^18^F\]F13640, and the muscarinic M~1~ ligand \[^11^C\]LSN3172176 belong to this group. The binding of the dopamine D~2~, D~3~, and D~2/3~ ligands from this category has been shown to be sensitive to changes of endogenous neurotransmitter levels but for the dopamine D~1/5~ the results were negative, and there are currently no D~1/5~ agonists or antagonists that would be sensitive to endogenous dopamine levels. Sensitivity of \[^18^F\]F13714, \[^18^F\]F13640, and \[^11^C\]LSN3172176 to endogenous serotonin/acetylcholine has not yet been evaluated in primates, although \[^18^F\]F13640 was sensitive to serotonin levels in rats. Some of these compounds were radiolabeled with ^18^F or ^18^F‐versions of previously developed ^11^C‐tracers because the longer half‐life of fluorine‐18 makes an imaging agent more suitable for wide‐scale clinical use. \[^18^F\]sufentanil has been created as a longer half‐life alternative to \[^11^C\]carfentanil but was not further developed.[184](#med21552-bib-0184){ref-type="ref"}

The third and last category contains tracers that have only been evaluated in rodents. The dopamine D~1/5~ ligand (*S*)(+)\[^11^C\]SKF82957, the dopamine D~3~ ligand \[^18^F\]7‐OH‐FHXPAT, the µ/κ‐opioid agonist \[^11^C\]PEO, and the muscarinic agonist \[^11^C\]AF‐150*(S)* fit in this category.

Binding of (*S*)(+)\[^11^C\]SKF82957 is known to be insensitive to changes of endogenous neurotransmitter levels. Available data for \[^11^C\]AF‐150(*S*) in this regard are inconclusive, and for other tracers from this category sensitivity to endogenous neurotransmitter levels has not yet been evaluated.

In the process of tracer development, some agonist tracers were found to have issues that hamper their routine application. Two radioligands for dopamine D~1/5~ receptors, (*R*)‐\[^11^C\]SKF82957 and (*S*)‐\[^11^C\]N‐methyl‐NNC 01‐0259,[81](#med21552-bib-0081){ref-type="ref"}, [185](#med21552-bib-0185){ref-type="ref"} are converted to lipophilic radioactive metabolites that penetrate into the brain and can confound the interpretation of imaging results, though this can be remedied by inhibiting the activity of the enzyme catechol‐O‐methyl transferase.[77](#med21552-bib-0077){ref-type="ref"} Another D~1/5~ agonist, \[^11^C\]SKF75670, was originally developed together with \[^11^C\]SKF82957 but was abandoned because of inferior signal‐to‐noise ratios. Since it is structurally very similar to \[^11^C\]SKF82957, it may show the same unfavorable in vivo metabolism.[78](#med21552-bib-0078){ref-type="ref"} The development of (*S*)‐\[^11^C\]N‐methyl‐NNC 01‐0259 was halted since tests examining its sensitivity to endogenous dopamine levels yielded a negative result.[80](#med21552-bib-0080){ref-type="ref"} The D~3~‐selective agonist tracer \[^18^F\]LS‐3‐134 was shown to specifically bind to D~3~ receptors in monkey brain but specific binding was only measurable under dopamine depletion conditions.[115](#med21552-bib-0115){ref-type="ref"} The muscarinic M~1~ receptor tracer \[^11^C\]AF‐150(*S*) showed both specific binding and sensitivity to endogenous acetylcholine levels in the rat brain but the low signal‐to‐noise ratios of this ligand cast doubt on its suitability for further research.[165](#med21552-bib-0165){ref-type="ref"}, [166](#med21552-bib-0166){ref-type="ref"}

To demonstrate the preferential binding of agonist tracers to receptor high‐affinity state, a head‐to‐head comparison with reference tracers binding to all receptors (ie, antagonist tracers) is required. For D~1/5~, D~2/3~, 5‐HT~1A~, and 5‐HT~2A~ agonist tracers counterpart antagonist tracers are available, which possess matching pharmacological selectivity (ie, bind with similar relative affinities to the same receptor subtypes within the relevant region of interest as their "corresponding" agonist tracers) and, in case of D~2/3~ and 5‐HT~2A~ ligands, sensitivity to endogenous neurotransmitter levels.[51](#med21552-bib-0051){ref-type="ref"}, [186](#med21552-bib-0186){ref-type="ref"}, [187](#med21552-bib-0187){ref-type="ref"}, [188](#med21552-bib-0188){ref-type="ref"} The same is true for the κ‐opioid agonist \[^11^C\]GR103545, which was developed along with its antagonist counterpart \[^11^C\]LY2795050,[189](#med21552-bib-0189){ref-type="ref"} and for the µ/κ‐opioid agonist \[^11^C\]PEO, which can be used in conjunction with the µ‐partial agonist and κ‐antagonist \[^11^C\]buprenorphine.[159](#med21552-bib-0159){ref-type="ref"} For the µ‐opioid agonist \[^11^C\]carfentanil, the M~2~ agonist \[^18^F\]FP‐TZTP and M~1~ agonists \[^18^F\]AF‐150(*S*) and \[^11^C\]LSN3172176 there are no suitable antagonist counterparts.[175](#med21552-bib-0175){ref-type="ref"}, [190](#med21552-bib-0190){ref-type="ref"} In theory, non‐subtype‐selective radioactive antagonists might be used in head‐to‐head comparisons with radioactive agonists if receptors to which the antagonist, but not the agonist, binds are fully blocked with a nonradioactive drug, but the feasibility of that approach is questionable because of the possible pharmacological effects of such blockade.

In conclusion, agonist tracers for PET imaging of dopamine D~2/3~, serotonin 5‐HT~1A~ and 5‐HT~2A~, µ and κ‐opioid, and M~2~ muscarinic receptors are available. Agonist tracers for dopamine D~1/5~ and muscarinic M~1~ receptors have issues that make their use for PET imaging problematic. Preference for the high‐affinity state in vitro has only been directly demonstrated for D~1/5~ and D~2/3~ tracers, some 5‐HT~1A~ tracers and the M~1~ tracer \[^18^F\]AF‐150(*S*). Agonist tracers for D~2/3~, 5‐HT~1A~, 5‐HT~2A~, and κ‐opioid receptors can be matched with antagonist tracers binding to the same receptors for head‐to‐head comparisons.

5. PROVING THE EXISTENCE OF THE HIGH‐AFFINITY STATE IN VIVO {#med21552-sec-0230}
===========================================================

5.1. Outcome measures of in vivo experiments {#med21552-sec-0240}
--------------------------------------------

In vivo experiments with neuroreceptor radioligands measure the availability of the receptors and changes in this availability in response to alterations of endogenous neurotransmitter levels or administration of exogenous drugs. Binding potentials (BPs) and target/nontarget ratios are "raw" measures representing receptor availability, which can later be recalculated to receptor densities or occupancies.

### 5.1.1. Binding potentials {#med21552-sec-0250}

The typical outcome measure of in vivo imaging experiments is the BP. This parameter is defined as the product of the density of binding sites (*B* ~max~) and the affinity of the radioligand for these sites (inverse of the dissociation constant, 1/*K* ~d~). BP is equal to the ratio of the concentrations of specifically bound and free ligand in the tissue of interest at equilibrium, provided that the administered dose of radioligand is sufficiently low (see the Appendix for more explanation). BP is estimated by fitting a kinetic model to measured time‐activity curves. Time‐dependent radioactivity in the region of interest and a reference region in the brain can be measured by PET imaging, and plasma radioactivity can be determined by blood sampling.[191](#med21552-bib-0191){ref-type="ref"} Note that in vivo not all receptors may be available for binding, as they can be internalized, converted to low‐affinity state (for an agonist) or occupied by neurotransmitter, so in the in vivo context the term *B* ~avail~ is more suitable than *B* ~max~.

Given the difficulty of determining the true concentration of the free ligand in the living tissue, other concentrations proportional to free ligand concentration in tissue are substituted in its place. Specifically, bound concentration is related to free plasma concentration (BP~F~), total plasma concentration (BP~P~), or "nondisplaceable" concentration (BP~ND~), that is, the total concentration of free and nonspecifically bound ligand in the tissue.[192](#med21552-bib-0192){ref-type="ref"} It is reasonable to assume that free ligand concentrations in the plasma and in the interstitial liquid of the brain tissue are equal at equilibrium, so BP~F~ can be considered the "true" BP.

### 5.1.2. Target/nontarget ratios {#med21552-sec-0260}

When regions of interest are small relative to PET camera resolution (ie, subsections of rodent brain) it is often hard to obtain a reliable time‐activity curve with high temporal resolution. Also, in situations when a lot of experimental conditions have to be tested and compared, it is often infeasible to obtain time‐activity curves by PET or to sacrifice large groups of animals at different time points. In these situations, one can take advantage of the "pseudoequilibrium" state when the concentration ratios between receptor‐rich and receptor‐free tissues remain constant even as absolute concentrations are changing. For a typical neuroreceptor ligand, one can reasonably expect the pseudoequilibrium state to be reached within half an hour after injection. Once the time range in which the pseudoequilibrium exists is validated, specific binding can be estimated from tissue concentrations at a single time point within this time range. Such concentrations can be obtained by ex vivo dissection and radioactivity counting or from a static PET scan. Target/nontarget concentration ratios can be used as is or be recalculated to specific binding ratios (SBRs): $$\text{SBR}{\  = \ ~}\frac{T - \text{NT}}{\text{NT}}\  = \ \frac{T}{\text{NT}}{- 1}.$$where T and NT are radioligand concentrations in receptor‐rich ("target") and receptor‐poor ("nontarget") regions of interest. In the absence of specific binding, SBR = 0, while T/NT = 1.

"Raw" specific binding, that is, the difference between radioligand concentrations in receptor‐poor and receptor‐rich regions can also be used as an outcome measure. However, when specific ligand binding is not normalized to the nonspecific binding at the same time point, its value is prone to intrasubject variations in pharmacokinetics. Therefore, the use of binding ratios is preferred.

### 5.1.3. Available receptor density {#med21552-sec-0270}

Available receptor density (*B* ~avail~) can be estimated in a saturation experiment. Specific binding of a radioligand is determined by two parameters: the density of binding sites in the region of interest (*B* ~avail~) and the affinity of the radioligand toward these receptors (1/*K* ~d~). To independently estimate these two parameters, bound and free radioligand concentrations at equilibrium have to be estimated at least at two different injected doses (for radiotracers, injected dose is usually varied by changing molar radioactivity). Bound concentration can be estimated from a difference in equilibrium tracer concentrations between the target and nontarget regions, while free concentration can be back‐calculated from the binding potential (see Appendix). *B* ~avail~ can then be quantified by regression analysis. In PET imaging, the regression is often performed on "linearized" binding data: binding potential is plotted against absolute specific binding (Scatchard plot). Scatchard plot requires a simple linear regression and is therefore straightforward but also bias‐prone, as the *X* and *Y* axes are not independent of each other. Alternatively, *B* ~avail~ can be estimated by nonlinear regression of the binding curve (bound vs free concentration plot). For in vitro assays, where free and bound ligand concentrations can be independently estimated, nonlinear regression is the gold standard. However, for in vivo experiments the Scatchard plot has remained popular.

### 5.1.4. Receptor occupancy {#med21552-sec-0280}

Displacement of a tracer from its receptors by a competing ligand decreases the binding potential of the tracer. Receptor occupancy can be calculated as the change in binding potential or target‐nontarget ratio after drug administration, relative to baseline. The same holds for the occupancy of the receptors by endogenous neurotransmitter, when drugs stimulating neurotransmitter release or depletion are administered.

5.2. Experimental paradigms used to demonstrate the existence of high‐affinity state in vivo {#med21552-sec-0290}
--------------------------------------------------------------------------------------------

To demonstrate that agonist tracers preferentially bind to a certain "high‐affinity" subset of receptors in vivo three approaches have been used (summarized in Table [2](#med21552-tbl-0002){ref-type="table"}). One approach is to directly measure the available binding site densities for agonist and antagonist tracers and demonstrate that the binding site density available to the agonist is lower. Another is to infer the ratio of high‐affinity binding site density to total binding site density from the results of experiments where tracers compete for binding to the receptors with unlabeled ligands. A third approach is to demonstrate that agonist, but not antagonist, binding can be influenced by manipulations of receptor‐G‐protein coupling.

###### 

Experimental paradigms used for the detection of high‐affinity state in vivo

  Approach                                        Experimental paradigm                                                                        Minimum ligand set necessary                                                 Minimum number of experimental conditions                                                                                  Results confirming the presence of high‐affinity state In vivo                                           Shortcomings                                                                                                    Examples                                                                                                                                                                                                               
  ----------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Binding site density comparison                 Saturation experiment                                                                        Labeled antagonist + la ‐ beled agonist                                      4 Minimum 2 dose levels per radioligand                                                                                    Lower *B* ~max~ value for agonist tracer than for antagonist tracer                                      Yes                                                                                                                                                                                                                                                                                                                                    [90](#med21552-bib-0090){ref-type="ref"}, [122](#med21552-bib-0122){ref-type="ref"}, [193](#med21552-bib-0193){ref-type="ref"}
  *B* ~avail~ = BP~F~ × *K* ~d~                   Labeled antagonist + labeled agonist                                                         2 Single dose level per radioligand                                          Lower *B* ~max~ value for agonist tracer than for antagonist tracer                                                        No                                                                                                       Requires arterial input with free fraction in plasma, in vitro *K* ~d~ is likely not equal to in vivo *K* ~d~   [70](#med21552-bib-0070){ref-type="ref"}                                                                                                                                                                               
  Correlation analysis                            Labeled antagonist + labeled agonist                                                         2 Single dose level per radioligand                                          Presence of the main trend with upward or downward deviations from it for certain regions of interest                      No                                                                                                       See Section [5.2.1](#med21552-sec-0300){ref-type="sec"}, third subsection                                       [70](#med21552-bib-0070){ref-type="ref"}, [132](#med21552-bib-0132){ref-type="ref"}, [137](#med21552-bib-0137){ref-type="ref"}, [139](#med21552-bib-0139){ref-type="ref"}                                              
  Imaging in disorders                            Labeled antagonist + labeled agonist                                                         4 Single dose level per radioligand, imaging in healthy and diseased state   Same specific binding for antagonist tracer in control and diseased state, different specific binding for agonist tracer   No                                                                                                       Upregulation or downregulation of high‐affinity state has to be demonstrated in vitro                           [103](#med21552-bib-0103){ref-type="ref"}, [194](#med21552-bib-0194){ref-type="ref"}, [195](#med21552-bib-0195){ref-type="ref"}                                                                                        
  Competition studies                             In vivo displacement curves                                                                  Labeled antagonist + unlabeled agonist                                       5 Minimum number of dose levels to distinguish between mono‐ and biphasic curves                                           Displacement curve better explained by biphasic than by monophasic model                                 Yes                                                                                                             large number of dose levels to test                                                                                                                                                                                    [86](#med21552-bib-0086){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"}, [197](#med21552-bib-0197){ref-type="ref"}, [198](#med21552-bib-0198){ref-type="ref"}
  Neurotransmitter challenge                      Labeled antagonist + labeled agonist + stimulator of neurotransmitter release or depletion   4 Single dose level per radioligand, imaging before and after challenge      Greater displacement of agonist tracer by the challenge of same magnitude                                                  Yes                                                                                                      see Section [5.2.2](#med21552-sec-0350){ref-type="sec"}                                                         [90](#med21552-bib-0090){ref-type="ref"}, [98](#med21552-bib-0098){ref-type="ref"}, [106](#med21552-bib-0106){ref-type="ref"}                                                                                          
  Exogenous drug challenge                        Labeled antagonist + labeled agonist + unlabeled agonist                                     4 Single dose level per radioligand, imaging before and after challenge      Greater displacement of agonist tracer by the challenge of same magnitude                                                  Yes                                                                                                                                                                                                                      [86](#med21552-bib-0086){ref-type="ref"}, [107](#med21552-bib-0107){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"}, [199](#med21552-bib-0199){ref-type="ref"}, [200](#med21552-bib-0200){ref-type="ref"}   
  Probing the nature of the high‐affinity state   Sensitivity to G‐protein coupling                                                            Labeled antagonist + la ‐ beled agonist + agent for G‐protein decoupling     4 Single dose level per radioligand, imaging before and after G‐protein decoupling                                         G‐protein decoupling decreases specific binding for the agonist but not for the antagonist radioligand   No                                                                                                              Requires intrathecal or intracerebral injections, does not look at what fraction of total receptors are in the high‐affinity state                                                                                     Proof of concept presented in[15](#med21552-bib-0015){ref-type="ref"}

John Wiley & Sons, Ltd.

It is important to emphasize that to compare agonist and antagonist tracers with each other their pharmacological selectivity profiles (ie, relative binding affinities toward different receptor subtypes) should be identical within the region of interest used for comparison. Otherwise, any detected difference in binding behavior could be attributed to the relative preference of one of the tracers toward a certain receptor subtype.

In principle, all experiments described below can be performed not only with PET tracers labeled with short‐lived positron‐emitting isotopes but also with radioligands labeled with long‐lived isotopes such as tritium (^3^H). On the one hand, this makes the experimental paradigm nontranslatable to the clinical setup. On the other hand, this enables the use of elegant approaches like the double‐tracer study, where radioligands labeled with short‐lived (eg, ^11^C) and long‐lived (eg, ^3^H) isotopes are compared head‐to‐head in the same group of animals.[194](#med21552-bib-0194){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"}

### 5.2.1. Approach 1: comparing binding site densities {#med21552-sec-0300}

#### Saturation study {#med21552-sec-0310}

As explained above, a minimum of two different radioligand doses needs to be tested to estimate binding site density (*B* ~avail~). More doses will add precision and can reveal potential cooperativity effects or the presence of multiple binding sites with different affinities (eg, receptor affinity states), provided that radioligand binding to all these sites is distinguishable from nonspecific binding. However, published PET studies comparing binding site densities of agonist and antagonist tracers were restricted to two doses.[90](#med21552-bib-0090){ref-type="ref"}, [193](#med21552-bib-0193){ref-type="ref"} Another study used single time point SBRs as outcome measure and built saturation curves based on 9 to 10 data points.[122](#med21552-bib-0122){ref-type="ref"}

In two‐dose PET studies aimed at quantifying *B* ~avail~, the low dose corresponds to the minimum amount of radioligand that can be injected, that is, the "tracer dose," which should occupy less than or equal to 10% of the receptor population in the region of interest. The high‐dose is chosen to occupy about two‐thirds of that population.[90](#med21552-bib-0090){ref-type="ref"}, [193](#med21552-bib-0193){ref-type="ref"}

#### Extracting density values from true binding potential measurements {#med21552-sec-0320}

It should be noted that performing a saturation assay with agonist radioligands can lead to unwanted and dangerous pharmacological effects, especially in the case of opioid ligands.[68](#med21552-bib-0068){ref-type="ref"}, [69](#med21552-bib-0069){ref-type="ref"}

In a head‐to‐head comparison of 5‐HT~1A~ agonist and antagonist tracers, Kumar et al[70](#med21552-bib-0070){ref-type="ref"} attempted to circumvent this problem by comparing the "true" binding potentials (BP~F~) for the two tracers at low injected dose instead of performing a second high‐dose scan to independently measure *B* ~avail~ and *K* ~d~. Given that BP~F~ = *B* ~avail~/*K* ~d~, *B* ~avail~ can arguably be calculated from the BP~F~ value using in vitro *K* ~d~ value for the corresponding tracer. However, there are two problems with this approach. First, to calculate BP~F~, one needs to obtain an arterial input curve and free fraction in plasma for the investigated radioligand, in addition to the time‐activity curve for the region of interest. Such a large amount of input data makes BP~F~ prone to experimental error and bias. Second, the in vivo *K* ~d~ of the radioligand is not necessarily equal to the in vitro *K* ~d~, especially if the latter is measured for receptors from a different animal species or in transfected cells.

#### Studying correlation between regional binding of agonist and antagonist {#med21552-sec-0330}

Binding potentials or target/nontarget ratios for an agonist tracer in various brain regions can be plotted against the corresponding measurements for an antagonist tracer, to examine their correlation. Such a plot may provide insight into the relationship between the densities of available binding sites for agonist and antagonist tracers while staying below the "tracer" threshold. If agonist binding in a certain brain region lies above the main trend on the correlation graph, it suggests that the relative abundance of receptors in the high‐affinity state in this region is higher than average, and vice versa.

This approach, however, has many limitations. If the relative abundance of the high‐affinity state is drastically different in each region, the correlation graph will be meaningless: there will be no main trend to pinpoint deviations from. If the relative abundance of the high‐affinity state is the same in all regions, the correlation graph will be a straight line, revealing no differences in agonist and antagonist binding and thus no evidence in favor of the existence of the high‐affinity state. Therefore, analysis of the correlation between agonist and antagonist binding cannot be the sole method of looking for the existence of high‐affinity state but can be an extra piece of data analysis in experiments based on other paradigms.

#### Studying agonist binding in disorders presumably caused by high‐affinity state dysregulation {#med21552-sec-0340}

In vitro experiments in membrane homogenates suggest that some neuropsychiatric disorders are accompanied by alterations in the relative abundance of the high‐affinity state in a given receptor population, while changes in overall receptor density relative to the healthy condition are either absent or much less pronounced. One example is animal models of psychosis where the high‐affinity state of dopamine D~2/3~ receptors is upregulated.[14](#med21552-bib-0014){ref-type="ref"}, [201](#med21552-bib-0201){ref-type="ref"}

Therefore, another way to demonstrate the existence of a high‐affinity state in vivo is to show that its upregulation (or downregulation) can be noninvasively detected by agonist tracers. If the relative abundance of the high‐affinity state is altered but the overall receptor density remains (relatively) constant, the binding of the agonist but not of the antagonist tracer will be different in the diseased state relative to the healthy state. Ratios of BP or SBR values for agonist and antagonist tracers can be used as outcome measures to normalize for possible concomitant alterations in total receptor density.[202](#med21552-bib-0202){ref-type="ref"}

In this paradigm, the binding of each tracer only has to be assessed at a low and pharmacologically inactive dose. However, one has to demonstrate that the relative abundance of high‐affinity state really differs between healthy and diseased states, using experimental approaches other than PET (typically, in vitro assays). Moreover, in the diseased state, alteration of the relative abundance of the high‐affinity state may be accompanied by alterations in other parameters relevant for radioligand binding. For instance, changes in baseline neurotransmitter levels also differentially affect the binding of agonist and antagonist tracers (agonist binding is changed to a greater extent). Concomitant changes in several parameters pressing agonist tracer binding in different directions can offset each other, leading to little or no change in overall receptor availability to the agonist tracer compared with the healthy state.

### 5.2.2. Approach 2: studying tracer vulnerability to displacement by an unlabeled competitor {#med21552-sec-0350}

One important difference between tracer‐drug competition experiments in vitro and in vivo is that in the latter case the concentration of both tracer and drug at the receptors is not constant. While for the radioligand a true equilibrium between its concentrations in blood and brain tissue can be achieved by using bolus‐plus‐infusion injection scheme, the same is virtually infeasible for the unlabeled drug (tissue concentrations of which are much harder to monitor). Nevertheless, one can usually safely assume that the pharmacokinetics of the competing drug are dose‐linear within the investigated dose range, so the degree of displacement of the tracer by the drug is also dose‐linear.

#### Building in vivo displacement curves {#med21552-sec-0360}

In vitro, the high‐affinity state is detected by displacing an antagonist radioligand with ever increasing concentrations of unlabeled agonist drug. When the remaining specific binding of the radioligand is plotted against agonist concentrations, the displacement is shown to proceed in two phases: agonist first displaces the radioligand from high‐affinity sites then from low‐affinity sites. The same displacement curve can be built in vivo by plotting binding potentials or target/nontarget ratios for an antagonist tracer against an administered dose of unlabeled agonist drug.

The advantage of this paradigm is that it does not require an agonist radioligand. Antagonist radioligands are much more numerous than agonist radioligands, so the displacement curve paradigm is currently applicable to a wider range of receptors than other paradigms mentioned below.

The downside, however, is that the generation of a displacement curve is a laborious undertaking. The shape of the biphasic curve is determined by five parameters: maximum binding level (at no displacement), minimum binding level (full displacement), agonist affinities for high‐ and low‐affinity states, and the percentage of receptors in the investigated population configured in the high‐affinity state. This means that at least five different dose levels (including zero) have to be used to test whether the obtained curve is monophasic or biphasic.

Therefore, studies that used the displacement curve approach typically used SBRs obtained ex vivo at a single time point from large numbers of rodents,[86](#med21552-bib-0086){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"} though the use of PET scanning in primates has also been reported.[197](#med21552-bib-0197){ref-type="ref"}, [198](#med21552-bib-0198){ref-type="ref"} The actual number of dose levels tested was 6 to 9 in rodent and 9 in non‐human primates.

#### Comparing vulnerability to displacement by unlabeled agonist {#med21552-sec-0370}

An agonist tracer should be more vulnerable than an antagonist tracer to displacement (or "challenge") by other agonists because it competes with them for the same subpopulation of receptors. Displacement can be elicited by administering an appropriate agonist drug or by stimulating endogenous neurotransmitter release.

The advantage of using exogenous agonist drugs for displacement is that these drugs can be selected to be subtype‐specific and to only occupy the receptor population that is being imaged (or even a defined subset of this population if the tracer binds to more than one receptor subtype).

On the other hand, manipulating neurotransmitter levels has the advantage of being "natural": one looks at the competition of the tracer with the endogenous ligand, the action of which on the receptors is thought to govern the functioning of the brain \[see Laruelle[187](#med21552-bib-0187){ref-type="ref"} and Finnema[51](#med21552-bib-0051){ref-type="ref"} for reviews\]. One can also reasonably expect that the competition will only happen at receptors that are really situated in the synapses. Moreover, neurotransmitter levels can be both increased and decreased relative to the baseline. In the latter case, the expected result is greater increase, rather than greater decrease, of binding for the agonist tracer. However, manipulating neurotransmitter release has its downsides, too. First, the effect vs time relationship between the administration of the drug that stimulates a rise or fall in endogenous neurotransmitter level and synaptic receptor occupancy is more complex than when receptors are occupied with exogenous agonist. Second, the released neurotransmitter can act on other receptor subtypes beyond the one being imaged. Third, some drugs used to manipulate neurotransmitter levels are known to manipulate levels of several neurotransmitters at once (eg, amphetamine stimulates both dopamine and norepinephrine release). The lack of selectivity regarding what neurotransmitter is manipulated and which receptors are occupied can confound the interpretation of cause‐and‐effect relationships.

If the "tracer condition" is satisfied (radioligands occupy a negligible fraction of all receptors), the ratio of agonist and antagonist radioligand vulnerabilities to displacement by a challenge is a constant value as long as less than 100% of the high‐affinity state is occupied as a result of the challenge (Figure [8](#med21552-fig-0008){ref-type="fig"}). Therefore, in theory, a single dose of agonist drug or neurotransmitter level manipulator should provide enough information to compare the vulnerability of agonist and antagonist tracers. In practice, because the actual percentage of receptors in the high‐affinity state is unknown, several doses are often tried, resulting in occupancies of up to 100%,[86](#med21552-bib-0086){ref-type="ref"}, [90](#med21552-bib-0090){ref-type="ref"}, [107](#med21552-bib-0107){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"} except in the human studies where the maximum challenge magnitude is limited by ethical considerations.[93](#med21552-bib-0093){ref-type="ref"}, [102](#med21552-bib-0102){ref-type="ref"}

![Relationship between agonist and antagonist tracer displacement (∆*B* ~Ag~ and ∆*B* ~An~) and the fraction of receptors occupied by competing agonist drug or neurotransmitter. *B* ~max~ is the total receptor density available at baseline, *X* ~H~ is the fraction of receptors configured in the high‐affinity state, *B* ~occ~ is the amount of receptors occupied as a result of the challenge. If *B* ~occ~ \< *X* ~H~ *B* ~max~, that is, not all high‐affinity state receptors become occupied, the ratio of relative decreases of agonist and antagonist tracer binding is constant and equal to 1/*X* ~H~](MED-39-1014-g008){#med21552-fig-0008}

An important limitation of the vulnerability comparison paradigm is that preference for the high‐affinity state is not the only factor influencing the vulnerability of the radioligand to displacement by unlabeled drugs. For instance, many preclinical in vivo tracer binding experiments are performed in anesthetized animals, and isoflurane and ketamine anesthesia were found to increase the baseline binding of agonist D~2/3~ tracers, exaggerating the vulnerability of agonist tracers relative to antagonists.[109](#med21552-bib-0109){ref-type="ref"}, [203](#med21552-bib-0203){ref-type="ref"} The mechanism of such selective influence is unclear, although there are reports that anesthetics interfere with receptor‐G‐protein (un)coupling [204](#med21552-bib-0204){ref-type="ref"}, [205](#med21552-bib-0205){ref-type="ref"} and alter endogenous neurotransmitter levels.[206](#med21552-bib-0206){ref-type="ref"}, [207](#med21552-bib-0207){ref-type="ref"}

Furthermore, D~2/3~ antagonist tracers are known to differ between themselves in the sensitivity to changes in dopamine levels.[187](#med21552-bib-0187){ref-type="ref"}, [208](#med21552-bib-0208){ref-type="ref"} The underlying reasons can be more or less favorable binding kinetics (see Finnema et al[51](#med21552-bib-0051){ref-type="ref"}, [209](#med21552-bib-0209){ref-type="ref"} for discussion) or differences in affinity toward the surface and internalized receptors.[210](#med21552-bib-0210){ref-type="ref"}, [211](#med21552-bib-0211){ref-type="ref"} Although a head‐to‐head comparison of D~2/3~ agonist \[^11^C\]MNPA and D~2/3~ antagonist \[^18^F\]fallypride in internalization‐deficient mice demonstrated that competition with the neurotransmitter is sufficient to explain short‐term (though not long‐term) changes in binding for both tracers,[44](#med21552-bib-0044){ref-type="ref"} this situation can be different for other receptor types.[43](#med21552-bib-0043){ref-type="ref"}

### 5.2.3. Studying vulnerability to G‐protein uncoupling in vivo {#med21552-sec-0380}

Addition of GTP or its analogs decreases specific binding of agonist but not antagonist ligands in vitro, so uncoupling of G‐proteins induced in vivo should lead to the same effects.

Seeman[15](#med21552-bib-0015){ref-type="ref"} demonstrated that GTP addition to tissues extracted from an animal after D~2/3~ agonist radioligand injection accelerates radioligand dissociation from D~2/3~ receptors in the tissue and proposed the use of pertussis toxin to promote G‐protein decoupling from the receptors in vivo. Indeed, physiological effects of dopamine and opioid receptor agonists were inhibited by pertussis toxin injections.[212](#med21552-bib-0212){ref-type="ref"}, [213](#med21552-bib-0213){ref-type="ref"}, [214](#med21552-bib-0214){ref-type="ref"}

This approach probes the nature of the high‐affinity state, that is, it seeks an answer to the question "is G‐protein binding to the receptor significant for agonist binding to the receptor?" However, this question is not the same as "do agonists bind to a subset of all receptors?," which is addressed in other paradigms. As discussed in Section [2](#med21552-sec-0020){ref-type="sec"}, all receptors may be precoupled to G‐proteins. Moreover, G‐protein decoupling agents (pertussis toxin or anything else) will have to be introduced locally into the region of interest rather than systemically through intravenous, intraperitoneal, or subcutaneous injections. For brain imaging, that means that intrathecal and intracerebral injections will have to be used. Such injections are technically challenging and hardly (if anyhow) translatable to the clinic. Therefore, this paradigm has not yet been used for head‐to‐head comparisons of agonist and antagonist radioligands.

5.3. Current evidence on the existence of high‐affinity state in vivo {#med21552-sec-0390}
---------------------------------------------------------------------

### 5.3.1. Dopamine receptors {#med21552-sec-0400}

The majority of studies attempting to demonstrate the existence of high‐affinity state in vivo has concerned dopamine D~2/3~ receptors. Agonists \[^11^C\](−)NPA, \[^11^C\]MNPA, and \[^11^C\](+)PHNO were compared with antagonists \[^11^C\]raclopride and \[^18^F\]fallypride. In some studies, these compounds were used in their unlabeled or ^3^H‐labeled forms. A large portion of these studies failed to demonstrate the existence in vivo of the subpopulation of D~2/3~ receptors configured in the high‐affinity state (see Skinbjerg et al[215](#med21552-bib-0215){ref-type="ref"} for review).

Binding site densities for D~2/3~ agonist and antagonist tracers were found to be equal in one study,[90](#med21552-bib-0090){ref-type="ref"} while in another study the average relative abundance of D~2/3‐high~ was found to be 79%,[193](#med21552-bib-0193){ref-type="ref"} which is close to the upper extreme of such percentages determined in vitro.[216](#med21552-bib-0216){ref-type="ref"} Saturation of \[^11^C\](+)PHNO binding in monkey brain was found to be biphasic but the two binding sites most probably corresponded to D~2~ and D~3~ receptor subtypes rather than to high‐ and low‐affinity states.[217](#med21552-bib-0217){ref-type="ref"}

In rats with brain lesions induced by the dopaminergic neurotoxin 6‐hydroxydopamine, binding levels of D~2/3~ antagonist \[^11^C\]raclopride and of D~2/3~ agonist \[^3^H\]PHNO were increased to the same extent.[194](#med21552-bib-0194){ref-type="ref"} No difference in baseline agonist binding relative to the healthy condition was found in dopamine β‐hydroxylase knockout (Dβh‐KO) mice,[103](#med21552-bib-0103){ref-type="ref"} in rats withdrawn from chronic ethanol and in amphetamine‐sensitized rats.[194](#med21552-bib-0194){ref-type="ref"} In these three animal models, an upregulation of D~2/3‐high~ was previously demonstrated in vitro by the group of Seeman et al.[201](#med21552-bib-0201){ref-type="ref"}, [218](#med21552-bib-0218){ref-type="ref"}, [219](#med21552-bib-0219){ref-type="ref"}, [220](#med21552-bib-0220){ref-type="ref"} However, in vitro measurements of elevated striatal D~2/3‐high~ in Dβh‐KO mice could not be replicated by the group that performed the in vivo imaging study.[103](#med21552-bib-0103){ref-type="ref"} Moreover, most of the data on the elevation of D~2/3‐high~ in ethanol‐withdrawn rats is based on comparison of *B* ~max~ values for antagonist radioligands in the presence and absence of GppNHp,[201](#med21552-bib-0201){ref-type="ref"}, [219](#med21552-bib-0219){ref-type="ref"} an indirect method of assessing D~2/3‐high~ abundance, shortcomings of which are discussed in Van Wieringen et al.[216](#med21552-bib-0216){ref-type="ref"}

In clinical studies of diseases where alteration of D~2/3‐high~ was suspected, binding potentials of agonist tracers in healthy and diseased subjects were similar,[202](#med21552-bib-0202){ref-type="ref"}, [221](#med21552-bib-0221){ref-type="ref"}, [222](#med21552-bib-0222){ref-type="ref"}, [223](#med21552-bib-0223){ref-type="ref"}, [224](#med21552-bib-0224){ref-type="ref"} although some recent reports buck this trend.[195](#med21552-bib-0195){ref-type="ref"}, [225](#med21552-bib-0225){ref-type="ref"}

The dopamine D~2/3~ antagonist radioligand raclopride (^11^C‐ or ^3^H‐labeled) was displaced by D~2/3~ agonist drugs in a monophasic manner.[86](#med21552-bib-0086){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"}, [197](#med21552-bib-0197){ref-type="ref"} In a more recent study, up to 70% of \[^11^C\]raclopride binding was displaced by D~2/3~ agonist quinpirole without any evidence of biphasicity.[39](#med21552-bib-0039){ref-type="ref"}

The majority of studies comparing agonist and antagonist tracers' vulnerability to displacement by agonist drugs found no difference in vulnerabilities,[86](#med21552-bib-0086){ref-type="ref"}, [107](#med21552-bib-0107){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"} though some reports confirming greater vulnerability of agonist tracers do exist [199](#med21552-bib-0199){ref-type="ref"}, [200](#med21552-bib-0200){ref-type="ref"} and the relative timing of tracer and drug administration were claimed to be important.[200](#med21552-bib-0200){ref-type="ref"}

Nevertheless, D~2/3~ agonists did prove to be more sensitive than antagonists to endogenous dopamine levels in anesthetized rodents,[44](#med21552-bib-0044){ref-type="ref"} cats,[90](#med21552-bib-0090){ref-type="ref"} primates,[92](#med21552-bib-0092){ref-type="ref"}, [98](#med21552-bib-0098){ref-type="ref"}, [106](#med21552-bib-0106){ref-type="ref"} as well as in awake humans,[93](#med21552-bib-0093){ref-type="ref"}, [102](#med21552-bib-0102){ref-type="ref"} though not in awake rodents,[86](#med21552-bib-0086){ref-type="ref"}, [194](#med21552-bib-0194){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"}, [203](#med21552-bib-0203){ref-type="ref"} with a single exception.[199](#med21552-bib-0199){ref-type="ref"} However, lack of consistency in preclinical data on neurotransmitter and agonist drug challenge raises a question whether this advantage of the agonists stems from their preference for the high‐affinity state or from other factors (see Section 5.2.2).

For dopamine D~1/5~ receptors, an in vivo displacement curve was built in baboons using the D~1~‐antagonist \[^11^C\]NNC‐112 and the D~1~‐agonist drug DAR‐0100A.[198](#med21552-bib-0198){ref-type="ref"} Occupancies above 40% were not investigated, but the best‐fit curve was monophasic, not supporting the existence of a high‐affinity receptor subpopulation.

### 5.3.2. Serotonin receptors {#med21552-sec-0410}

A few head‐to‐head agonist‐antagonist comparisons done with serotonin receptor radioligands yielded ambiguous results.

Two studies found that about 80‐90% of the specific binding of antagonist 5‐HT~1A~ ligand \[^11^C\]WAY‐100635 could be displaced by the 5‐HT~1A~ agonist 8‐OH‐DPAT,[226](#med21552-bib-0226){ref-type="ref"}, [227](#med21552-bib-0227){ref-type="ref"} but in both cases only a single dose of the agonist was tried, so it is impossible to say whether 8‐OH‐DPAT displaces \[^11^C\]WAY‐100635 in a monophasic or a biphasic manner. In an ex vivo saturation study, the binding site density of 5‐HT~1A~ agonist \[^3^H\]CUMI‐101 was 33% lower than that of the antagonist \[^3^H\]MPPF in rat frontal cortex, but 82% higher in rat hippocampus.[122](#med21552-bib-0122){ref-type="ref"} BP~F~ values for \[^11^C\]CUMI‐101 across the baboon brain were about 45% of BP~F~ values for 5‐HT~1A~ antagonist \[^11^C\]WAY‐100635,[70](#med21552-bib-0070){ref-type="ref"} while in vitro *K* ~d~ values for the two tracers were comparable, but these findings should be interpreted with caution for reasons described in the subsection "Extracting density values from true binding potential measurements" of Section [5.2.1](#med21552-sec-0300){ref-type="sec"}. Yet another study found considerable differences between the binding patterns of 5‐HT~1A~ agonist \[^18^F\]F13174 and 5‐HT~1A~ antagonist \[^18^F\]MPPF in marmosets: regional BP~ND~ values even did not correlate when animals were imaged without the use of anesthesia.[132](#med21552-bib-0132){ref-type="ref"} However, the variability of data (especially for \[^18^F\]F13174) was high, so it is hard to draw any firm conclusions regarding the existence of separate 5‐HT~1A~ receptor subpopulations recognized by \[^18^F\]F13174 and \[^18^F\]MPPF from the study.

Regional BP~ND~ values of the 5‐HT~2A~ agonist \[^11^C\]CIMBI‐36 were compared with regional BP~ND~ values of the 5‐HT~2A~ antagonist \[^11^C\]MDL100907 in monkeys [137](#med21552-bib-0137){ref-type="ref"} and regional BP~ND~ values of another 5‐HT~2A~ antagonist \[^18^F\]altanserin in humans.[139](#med21552-bib-0139){ref-type="ref"} Both analyses did yield deviations from linear correlation in the hippocampus and choroid plexus, but these could all be explained by the binding of \[^11^C\]CIMBI‐36 to 5‐HT~2C~ receptors. In a recent non‐human primate study, \[^11^C\]CIMBI‐36 turned out to be more sensitive than \[^11^C\]MDL100907 to fenfluramine‐induced serotonin release,[142](#med21552-bib-0142){ref-type="ref"} but, as discussed above for D~2/3~ radioligands, this does not per se prove that \[^11^C\]CIMBI‐36 preferentially binds to the high‐affinity state of 5‐HT~2A~ receptors in vivo.

To sum up, the majority of data, both for dopamine and serotonin receptors, does not directly support the existence of a receptor subpopulation in vivo to which agonists preferentially bind. There are some undisputable differences in the behavior of agonist tracers and antagonist tracers, such as specific sensitivity of the former to anesthesia and greater sensitivity to synaptic neurotransmitter levels, but the reason for these differences is not clear.

5.4. Experimental data in light of the nature of the high‐affinity state {#med21552-sec-0420}
------------------------------------------------------------------------

Some attempts to detect the high‐affinity state in vivo may have failed because the used radioligands were not sufficiently subtype‐selective or lacked sufficient intrinsic acitivity via the canonical GPCR pathway.[118](#med21552-bib-0118){ref-type="ref"}, [119](#med21552-bib-0119){ref-type="ref"}, [228](#med21552-bib-0228){ref-type="ref"} In other cases, however, the reasons for failure were completely unclear. Therefore, the nature and functioning of the high‐affinity state in vivo has remained elusive.

Two explanations of the failure to detect high‐ and low‐affinity states in vivo have been put forward. One explanation proposes that all, or almost all, receptors are configured in the high‐affinity state in vivo [86](#med21552-bib-0086){ref-type="ref"} and permanently precoupled to G‐proteins, so that these G‐proteins, at least their Gα subunits, do not dissociate from the receptors after activation.[215](#med21552-bib-0215){ref-type="ref"} Another explanation states that, whatever the baseline degree of receptor‐G‐protein precoupling, receptors can and do recruit new G‐proteins when occupied by agonists, so high agonist concentrations eventually make all receptors bind G‐proteins and thus convert to the high‐affinity state.[196](#med21552-bib-0196){ref-type="ref"}, [198](#med21552-bib-0198){ref-type="ref"} Indeed, receptors have been subjected to high agonist (drug or neurotransmitter) concentrations in virtually all experimental paradigms used for in vivo detection of the high‐affinity state **(**Table [2](#med21552-tbl-0002){ref-type="table"} **)**. In vivo imaging experiments last for tens of minutes, while time constants for receptor and G‐protein activation and for receptor‐ligand and receptor‐G‐protein binding vary from tens of milliseconds to a few seconds.[37](#med21552-bib-0037){ref-type="ref"} Gradual G‐protein recruitment in response to agonist binding can thus confound experimental outcomes in currently used paradigms and can "inflate" the apparent relative abundance of the high‐affinity state in vivo. Indeed, in studies comparing the vulnerability of dopamine D~2/3~ agonist and antagonist tracers to drug challenge, the lowest doses of D~2/3~ agonist drugs and the dopamine release stimulator amphetamine (resulting in the lowest receptor occupancies and therefore minimal G‐protein recruitment) tended to produce the greatest relative difference between agonist and antagonist tracer displacement. In three such studies, the lowest dose of challenge drugs resulted in zero or negative displacement of the antagonist \[^11^C\]/\[^3^H\]raclopride but positive (though small and not statistically significant) displacement of agonist tracers \[^11^C\]/\[^3^H\]PHNO and \[^11^C\]/\[^3^H\]MNPA.[86](#med21552-bib-0086){ref-type="ref"}, [107](#med21552-bib-0107){ref-type="ref"}, [196](#med21552-bib-0196){ref-type="ref"} Superior sensitivity of D~2/3~ agonists to amphetamine‐induced dopamine release in humans compared to the D~2/3~ antagonist \[^11^C\]raclopride was demonstrated at receptor occupancies of 22% or lower.[93](#med21552-bib-0093){ref-type="ref"}, [102](#med21552-bib-0102){ref-type="ref"} Finally, the D~2/3~ agonist \[^3^H\]PHNO was found to be more vulnerable than \[^3^H\]raclopride to displacement by the agonist (−)NPA when this agonist was co‐injected with the radioligands instead of being injected sometime before their administration, although this study used non‐normalized "raw" specific binding as outcome measure.[200](#med21552-bib-0200){ref-type="ref"}

Comparison of the in vivo imaging results with available in vitro data on detection of the high‐affinity state raises even more questions. There are no systematic reviews of in vitro studies assessing the percentage of receptors configured in the high‐affinity state for nondopaminergic receptors. However, recently published reviews dedicated to the affinity states of D~2/3~ receptors [216](#med21552-bib-0216){ref-type="ref"}, [229](#med21552-bib-0229){ref-type="ref"} demonstrate not only the lack of agreement but also the absence of a trend in the assessments of the abundance of the high‐affinity state of D~2/3~ receptors in different setups**:** (i)Experiments in membrane homogenates from transfected cells and isolated tissues consistently showed that a significant portion of D~2/3~ receptors is configured in the low‐affinity state. Only about 20% of dopamine D~2/3~ receptors in the rodent brain and about 30% in the human brain are in the high‐affinity state.[216](#med21552-bib-0216){ref-type="ref"}(ii)No high‐affinity state of D~2/3~ receptors could be detected on intact cells. In bovine pituitary membranes, 55% of D~2/3~ receptors were in the high‐affinity state, but intact dispersed pituitary cells had only low‐affinity state.[230](#med21552-bib-0230){ref-type="ref"} Similar results were demonstrated with transfected HEK293T and T‐REx‐293 cells expressing D~2~ receptors.[28](#med21552-bib-0028){ref-type="ref"}, [42](#med21552-bib-0042){ref-type="ref"} One study found 16% of D~2~ receptors on cultured rat pituitary adenoma cells configured in the high‐affinity state using \[^3^H\]domperidone as a radioligand,[231](#med21552-bib-0231){ref-type="ref"} but these results have yet to be replicated.(iii)Autoradiographic studies where densities (B~max~) of D~2/3~ receptors in tissue slices were estimated, tended to produce lower B~max~ values for agonist than for antagonist radioligands, but the variance between studies was too high to consider the difference significant.[229](#med21552-bib-0229){ref-type="ref"} The majority of antagonist vs agonist drug displacement experiments demonstrated a single high‐affinity population of D~2/3~ receptors in tissue slices in vitro.[229](#med21552-bib-0229){ref-type="ref"} This is in agreement with the data from in vivo imaging (see Section [5.3.1](#med21552-sec-0400){ref-type="sec"}).

To explain the low relative abundance of the high‐affinity state in membrane homogenates within the precoupling model of receptor‐G‐protein interaction, one can assume that partial dissociation of receptor‐G‐protein complexes occurs during membrane preparation, but the exact mechanism is hard to define. Alternatively, one can assume the existence of a large intracellular reserve of receptors in the high‐affinity state. In transfected cells, the affinity of agonist ligands used as PET tracers toward internalized D~2/3~ receptors was shown to be about twofold lower than toward surface receptors,[42](#med21552-bib-0042){ref-type="ref"} a change that would hardly be noticeable in saturation or competition curves. However, the total densities of D~2/3~ receptors measured in membrane homogenates by radioligand binding saturation and in vivo by PET are in good agreement,[229](#med21552-bib-0229){ref-type="ref"} which does not support the existence of extra D~2/3~ receptors that are detectable in vivo but are not found in membrane homogenates.

The collision coupling model of receptor‐G‐protein interaction can be reconciled with measurements of the high‐affinity state in membrane homogenates if one assumes that in these homogenates only a fraction of the total G‐protein pool of the cell is available for recruitment to the receptors. Indeed, the number of G‐proteins in living cells is likely equal to or much greater than the number of their cognate receptors.[45](#med21552-bib-0045){ref-type="ref"}, [232](#med21552-bib-0232){ref-type="ref"}, [233](#med21552-bib-0233){ref-type="ref"} However, given that G‐proteins are anchored to the lipid bilayer,[234](#med21552-bib-0234){ref-type="ref"} it is not clear how such G‐protein reserve can both be easily accessible in the living tissue and become lost in membrane homogenates. Especially the findings of Seeman[200](#med21552-bib-0200){ref-type="ref"} are puzzling in this regard. In that study, IC~50~ values for the displacement of \[^3^H\](+)PHNO and \[^3^H\]raclopride from striatal membranes by (−)NPA were measured. When radioligands and (−)NPA were added to the membranes simultaneously, the IC~50~ value observed for \[^3^H\](+)PHNO was sevenfold lower than for \[^3^H\]raclopride. However, when (−)NPA was added to the membranes 30 minutes earlier than the radioligands, the difference in IC~50~ values for \[^3^H\](+)PHNO and \[^3^H\]raclopride was only twofold. Similar vulnerabilities of \[^3^H\]raclopride and \[^3^H\](+)PHNO in the case of (−) NPA pre‐incubation could mean that (−)NPA can and does stimulate G‐protein recruitment to all or almost all receptors in the membranes, while greater vulnerability of \[^3^H\](+)PHNO in case of simultaneous addition may mean that in the absence of an agonist, only some receptors are G‐protein‐bound and therefore accessible to \[^3^H\](+)PHNO. However, in those experiments, radioligands were equilibrated with membrane homogenates for 2 hours before readout, which is much longer than the pre‐incubation step. Therefore, even in the case of simultaneous addition of radioligands and (−)NPA, there should have been enough time during the equilibration step for (−)NPA to elicit recruitment of "spare" G‐proteins to the receptors.

The absence of the high‐affinity state of D~2/3~ receptors in isolated intact cells ^28,42,230^ is even harder to reconcile with either of the two models mentioned above. Collision coupling at least provides a theoretical explanation of the disappearance of high‐affinity state upon agonist addition due to a high level of GTP in living cells. Still it remains puzzling why agonists force D~2/3~ receptors in dispersed cells from a natural tissue (bovine pituitary) to uncouple from G‐proteins (convert into the low‐affinity state), but promote G‐protein recruitment (conversion to the high‐affinity state) when they are acting on the same receptors in intact tissue.

Switching from the G‐protein‐dependent high‐affinity state model to the oligomerization‐dependent model leaves the same questions open: it is not clear how the degrees of receptor oligomerization can be different in membranes, dispersed cells and living tissues. Moreover, observation of almost all receptors configured in high‐affinity state in vivo is hard to reconcile with the oligomerization‐dependent model. At full oligomerization and full agonist occupancy, cooperativity‐induced high‐affinity state can have a relative abundance of no more than 50% (in the case of dimers), and higher values imply that few, if any, receptors are oligomerized.

6. CONCLUSION {#med21552-sec-0430}
=============

The concept of the high‐affinity state postulates that a certain subset of receptors in the living brain is primarily responsible for signaling. Assessing the abundance of this subset is thus potentially very relevant for studies concerning the responses of neurotransmission to pharmacological or physical stimuli and the dysregulation of neurotransmission in neurological disorders.

A number of experimental paradigms have been developed for the estimation of the relative abundance of receptors configured in the high‐affinity state. The high‐affinity state is preferentially recognized by agonists in vitro, so the development of agonist PET tracers as tools for the noninvasive imaging of the high‐affinity state has become popular in recent decades.

The greatest number of agonist tracers has been developed for dopamine D~2/3~ receptors, but agonist tracers for dopamine D~1~, µ‐opioid, and muscarinic M~2~ receptors are also known, and in recent years, radiolabeled agonists for serotonin 5‐HT~1A~ and 5‐HT~2A~, κ‐opioid and muscarinic M~1~ receptors have appeared. It should be noted, however, that for many of the nondopaminergic tracers the actual preference for the high‐affinity state has not been directly tested, because functional agonism is often assumed to imply preferential binding to the high‐affinity state.

For dopamine, serotonin and κ‐opioid receptors, head‐to‐head comparisons of agonist and antagonist tracers are now possible, while matching antagonist tracers for muscarinic M~2~ and µ‐opioid receptors have yet to be developed. Given that, beyond head‐to‐head agonist‐antagonist comparisons, antagonist tracers are also suitable for experiments like displacement curve generation (see Section [5.2.2](#med21552-sec-0350){ref-type="sec"}), development of new antagonist tracers for muscarinic M~2~ and µ‐opioid receptors with a pharmacological selectivity matching that of existing agonist tracers will arguably be more useful for the assessment of the affinity states of these receptors than development of new agonist tracers.

Agonist tracers appear to be more sensitive to endogenous neurotransmitter challenge, as was originally expected. However, other expectations regarding agonist tracers have not been fulfilled. Agonist imaging did not reveal alterations in the relative abundance of the high‐affinity state in neurological disorders. The benefits of agonist tracers for the imaging of receptor occupancies by drugs have also not been proven.

Moreover, though the separation of GPCRs into subsets with high‐ and low‐affinity state is consistently observed in membrane homogenates in vitro, data from preclinical and clinical experiments do not support the existence of the high‐ and low‐affinity states in vivo. The majority of these data concerns dopamine D~2/3~ receptors but recent results on serotonin receptors paint the same picture.

The relative abundance of the high‐affinity state in vivo may simply be close to (or equal to) 100%, making the detection of low‐affinity state unfeasible. It is also possible that agonist drugs or tracers used for in vivo experiments may inflate the relative abundance of the high‐affinity state.

Critical revision of experimental approaches and collection of experimental evidence for nondopaminergic receptors will help clarify whether the high‐affinity state of GPCRs exists in vivo and whether agonist tracers really have advantages over antagonist tracers because of their preferential binding to the high‐affinity state.
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CALCULATION OF BINDING POTENTIALS {#med21552-sec-0440}
=================================

The ratio of the concentrations of specifically bound tracer (*B*) and free tracer (*F*) in the tissue at equilibrium is equal to the ratio of available receptor density and ligand‐receptor affinity (*B* ~max~/*K* ~d~) when the tracer only occupies a negligible fraction of all receptors (Figure [A1](#med21552-fig-0009){ref-type="fig"}).

![Relationship between the fraction of ligand‐occupied receptors and *B*/*F* ratio. At equilibrium, *B*/*B* ~max~ = *F*/(*F* + *K* ~d~), therefore *B*/*F* = *B* ~max~/(*F* + *K* ~d~). If *F* ≪ *K* ~d~, then *B* ≪ *B* ~max~ and *B*/*F* \~ *B* ~max~/*K* ~d~. Note that at low concentrations (*F*/*K* ~d~ ≪ 1), the ligand occupies only a small part of total receptor population, and the *B*/*F* ratio (binding potential) is stable (left part of the graph)](MED-39-1014-g009){#med21552-fig-0009}

In practice, specifically bound tracer concentration *B* is often calculated as a difference between tracer concentrations in a receptor‐rich region of interest and a receptor‐poor reference region. Free tracer concentration, on the other hand, is replaced with directly measurable concentrations that are linearly dependent on "true" *F* at equilibrium.[192](#med21552-bib-0192){ref-type="ref"} These concentrations can be: --Free tracer concentration in plasma (equal to *F* if the tracer is transferred from tissue to plasma by passive diffusion);--Total, that is, free and protein‐bound, tracer concentration in plasma;--Nondisplaceable, that is, free and nonspecifically bound, tracer concentration in tissue.

To determine tracer concentration in plasma (whether free or total) one needs to obtain arterial plasma samples, which is an invasive procedure. Therefore, the last option is the most popular: tracer concentration in receptor‐rich tissue is related to tracer concentration in receptor‐poor tissue.

Binding potentials are defined at equilibrium. Plasma and tissue concentrations of a tracer can be directly equilibrated with each other by administering the tracer in an infusion but such paradigms are hard to implement. Therefore, in most positron emission tomography (PET) and single‐photon emission computed tomography (SPECT) studies tracer is administered via a simple bolus injection. In that case, to calculate binding potentials, time‐activity curves for regions of interest are used as input data for so‐called kinetic modeling. A compartmental model is built up based on relevant theories. Tracer distribution is described in terms of its transfer between virtual compartments (like "free tracer," "nonspecifically bound tracer," and "specifically bound tracer"). The model is fitted to the time‐activity curves acquired by the PET camera. If the model can adequately describe the experimental curves, the values of individual kinetic parameters or their combinations are determined from the model fit. Fewer fitting parameters often mean a more robust fit, so many simplifying assumptions are often made. Graphical analyses, simplifying the fitting process to linear regression, are also widely used.[235](#med21552-bib-0235){ref-type="ref"}, [236](#med21552-bib-0236){ref-type="ref"} Fitted parameters are then used to obtain binding potentials, essentially by extrapolating the kinetics observed in the imaging experiments to the situation of equilibrium.
